

Appendices

Appendix A

First Published Report of Prader-Willi Syndrome

Note: The first published description of the condition that we now know as Prader-Willi syndrome was authored by Swiss doctors Andrea Prader (Figure A.1), Alexis Labhart (Figure A.2), and Heinrich Willi (Figure A.3) and appeared in the journal *Schweizerische medizinische Wochenschrift* (*Swiss Medical Weekly* [SMW]) in 1956. Thanks to Dr. Urs Eiholzer, a protégé of Dr. Prader, and with copyright permission from the publisher of *SMW*, we are able to reproduce that first report in the original German as well as in an English translation with footnotes, commentary, and historical photographs. Dr. Phillip D.K. Lee assisted with editing the translation and footnotes.



Figure A.1. Andrea Prader, 1919–2001.




Figure A.2. Alexis Labhart, 1916–1994.



Figure A.3. Heinrich Willi, 1900–1971.

Ein Syndrom von Adipositas, Kleinwuchs, Kryptorchismus und Oligophrenie nach myatonieartigem Zustand im Neugeborenenalter*

A. Prader, A. Labhart, und H. Willi
(Universitätskinderklinik, Zürich)

Es handelt sich um ein Syndrom von Kleinwuchs, Akromikrie, Adipositas und Imbezibillität, dem im Säuglingsalter regelmässig eine extrem schwere Muskelhypotonie vorausgegangen ist. Neben variablen kleineren degenerativen Merkmalen findet man beim Knaben regelmässig ein hypoplastisches, flach verstrichenes Skrotum mit inguinaler oder abdominaler Hodenretention.

Bisher haben wir dieses Syndrom bei 5 männlichen und 4 weiblichen Patienten beobachtet. Der älteste Patient ist 23jährig und die älteste Patientin 15jährig. Die übrigen sind 5–10 Jahre alt. Jüngere Patienten haben wir vorläufig nicht miteinbezogen, da sie noch nicht das volle klinische Bild erkennen lassen.

Alle diese Patienten hatten als Neugeborene eine extreme Muskelhypotonie, die sich darin äussert, dass die Kinder fast ganz bewegungslos und schlaff daliegen und weder schreien noch saugen können, so dass einen längere Hospitalisierung notwendig ist. Die Sehnenreflexe sind in diesem Zeitpunkt nicht oder nur schwach auslösbar. Die Diagnose lautet regelmässig "Lebensschwäche" oder "Myatonia congenita". Nach einigen Wochen macht sich wider Erwarten eine leichte Besserung bemerkbar, doch dauert es Monate, bis die Säuglinge schreien und sich kräftig bewegen können.

Wohl als Folge dieser sich nur ganz allmählich bessernden Muskelhypotonie lernen die Kinder erst mit 1 Jahr sitzen und erst mit 2 Jahren gehen. Während die Hypotonie und Adynamie zusehends bessern, tritt ungefähr um das 2. Jahr die Adipositas auf, und gleichzeitig werden der Wachstumsrückstand und die Oligophrenie deutlich bemerkbar.

Neurologisch findet man nach dem 5. Jahr noch eine geringfügige Muskelhypotonie und eine gewisse motorische Unbeholfenheit, jedoch ein normales Reflexbild. Der Kopf ist im Verhältnis zur Körpergrösse eher klein. Im Röntgenbild fehlen signifikante Sellaveränderungen. Die dreimal durchgeführte Luft- und Elektroencephalographie ergab unauffällige Befunde.

Stoffwechseluntersuchungen konnten leider nur bei der Hälfte der Patienten durchgeführt werden. Der Grundumsatz ist normal. Mit Ausnahme des ältesten Patienten, bei dem mit 17 Jahren ein Diabetes mellitus aufgetreten ist, ergibt die Prüfung des KH-, Elektrolyt- und Wasserstoffwechsels mit den üblichen Untersuchungen normale Befunde. Zeichen einer Hypothyreose fehlen. Die Pubertätsentwicklung scheint verzögert und unvollständig zu sein. Die 17-Ketosteroide

*Reprinted with permission from Prader, Labhart, and Willi, Ein syndrom von adipositas, kleinwuchs, kryptorchismus und oligophrenie nach myatonieartigem zustand im neugeborenenalter. *Schweizerische Medizinische Wochenschrift*. 1956;86:1260–1261. Copyright © 1956 by the Swiss Medical Weekly.

der älteren Patienten sind auffallend tief. Die Gonadotropinausscheidung des 23-jährigen Patienten ist erhöht, d.h. es besteht wohl als Folge des Kryptorchismus ein hypergonadotroper Hypogonadismus. Der Vaginalabstrich des 15jährigen Mädchens zeigt eine deutliche Östrogenwirkung. Es scheint also keine Hypophyseninsuffizienz, sondern eher noch eine Hypothalamusstörung vorzuliegen. Bezüglich Ätiologie konnten wir bis jetzt weder für die Heredität noch für eine Embryopathie genügend Anhaltspunkte finden.

Zusammenfassend glauben wir, dass es sich um ein nicht so seltenes, gut abgegrenztes, einheitliches klinisches Syndrom handelt. Beim Säugling und Kleinkind erinnert es an die Myatonia congenita Oppenheim. Im Schulkindalter und später an die Dystrophia adiposogenitalis Fröhlich, an das Laurence-Moon-Biedl-Syndrom und an den hypophysären Zwergwuchs. Trotz mancher Ähnlichkeit lässt es sich aber von allen diesen Syndromen deutlich unterscheiden.

English translation:

A Syndrome Characterized by Obesity, Small Stature, Cryptorchidism and Oligophrenia Following a Myotonia-like Status in Infancy

**A. Prader, A. Labhart and H. Willi
(Zürich Children's Hospital)**

The syndrome to be described is characterized by small stature, acromicria,¹ obesity and imbecility, regularly preceded by extreme muscle hypotonia in infancy. Apart from variable minor degenerative characteristics, one generally finds in boys a hypoplastic, flat scrotum with inguinal or abdominal retention of testicles.

So far, we have found this syndrome in 5 male and 4 female patients. The oldest patient is 23 years old, the oldest female patient 15 years. The others are between 5 and 10 years old. For the time being, we have not included younger patients, since they do not present the entire clinical picture.

As neonates, all these patients had suffered from extreme muscle hypotonia, leading to the children lying almost entirely motionless and floppy, not being able to either cry or suck, resulting in prolonged stays in hospitals. Hardly any tendon reflexes can be found at that stage. Typically, "Congenital Myotonia" or "Lebensschwäche"² were diagnosed. Unexpectedly, some improvement was generally seen after several weeks, but it takes months before the infants are able to cry and move with ease.

Probably as a consequence of the very slowly improving muscle hypotonia, the children are only able to sit at 1 year of age and to walk at the age of 2 years. While the hypotonia and adynamia³ gradually improve, obesity sets in around the second year of life. At the same time, growth retardation and oligophrenia⁴ become distinct.

The neurologic findings persist after age 5 years. Despite some motor clumsiness, reflexes are normal. The size of the head is rather small in relation to body height. X-rays do not reveal any disturbances in the

sella⁵ area. The pneumo- and electro-encephalograms, performed three times, yielded normal results.

Metabolic tests could be conducted in only half of the patients but resulted in normal basal metabolic rates. Apart from the oldest patient, who had developed diabetes mellitus at the age of 17 years, tests of the carbohydrate, electrolyte and water metabolism yielded normal results when measured with conventional methods. No signs of hypothyroidism were found. Puberty seems to be delayed and incomplete. In the older patients, urinary 17-ketosteroid⁶ excretion measurements were very low. The gonadotropin secretion of the 23-year-old patient was increased, the cryptorchidism probably led to a hypergonadotropic hypogonadism. The vaginal smear of the 15-year-old girl revealed a distinct effect of estrogens, which makes a hypothalamic disorder more likely than pituitary insufficiency. Regarding aetiology, we were not able to find sufficient evidence for heredity or for embryopathy.

In summary, we believe that this syndrome is not all that rare, clearly distinguishable, and well defined. Whereas in infants, it shows some similarity to amyotonia congenita of Oppenheim,⁷ from school age on and later, it resembles Fröhlich's syndrome (adiposogenital dystrophy),⁸ the Laurence-Moon-Biedl-Bardet syndrome,⁹ and later, pituitary small stature.¹⁰ Despite all the similarities, it can be clearly distinguished from the syndromes mentioned.

Footnotes to translation:

1. Acromicria: small hands and feet.
2. Lebensschwache: literally, life-weak (e.g., listless, moribund).
3. Adynamia: lack of physical movement.
4. Oligophrenia: a type of mental retardation leading to social incompetence; "feeble-mindedness."
5. Sella, *or* sella turcica: the area of the skull that contains the pituitary gland.
6. 17-ketosteroids: a urinary test, commonly used in the past as a marker for androgen production.
7. Amyotonia congenita of Oppenheim: a condition of severe, usually nonprogressive neonatal hypotonia described by Hermann Oppenheim in 1900. It appears that this is not an actual condition, but a description of signs and symptoms that are seen in a number of neonatal neuromuscular conditions, most notably spinal muscular atrophy.
8. Fröhlich's (adiposogenital dystrophy) syndrome is usually used to describe a condition in which adolescent boys are noted to have obesity and hypogonadotropic hypogonadism. The original case was due to a pituitary tumor and subsequent cases have involved a similar etiology, whereas other cases may have had a variety of conditions. This term is not commonly used in current medical practice.
9. Laurence-Moon-Biedl-Bardet syndrome was actually described by Bardet and Biedl in the 1920s and is currently known as Bardet-Biedl syndrome. It is characterized by obesity, short stature,

- moderate mental retardation, retinal dystrophy, polydactyly, hypogonadism in males, and a variety of other abnormalities.
10. Pituitary short stature: e.g., growth hormone deficiency.

Commentary

The first description of the Prader-Willi syndrome—as it is now called—consisted of only 21 lines. The paragraphs above constitute the entire article—not just the abstract. The completeness and accuracy of this description and its pathophysiological implications meet with much admiration. Considering the limited methodological techniques of the time, this achievement becomes even more impressive. The description was so comprehensive that up until the 1980s, no substantial new knowledge was added.

Urs Eiholzer, MD
Head, Foundation Growth Puberty Adolescence
Zurich, Switzerland

Appendix B

A Comprehensive Team Approach to the Management of Prader-Willi Syndrome

Note: This document represents the consensus of an international meeting of PWS specialists on April 24, 2001, sponsored by the International Prader-Willi Syndrome Organization (IPSWO) and funded through a grant from Pharmacia Corporation. The consensus statement was originally edited by Dr. Urs Eiholzer in 2001 and subsequently revised with the assistance of Dr. Phillip D.K. Lee in 2004.*

Meeting Participants

Moderator and Presenter: Urs Eiholzer, MD, Head, Foundation Growth Puberty Adolescence Zurich, Switzerland

Other Presenters:

Margaret Gellatly, BSc (Hons), SRD, Hon Dietary Adviser, Prader-Willi Syndrome Association (UK), Chelmsford, UK

Phillip D.K. Lee, MD, Director, Division of Endocrinology and Metabolism, Children's Hospital of Orange County, Orange, California, USA [*Note:* Dr. Lee is currently Chief Scientific Officer, Immunodiagnostic Systems Ltd., Bolden, Tyne & Wear, UK]

Martin Ritzén, MD, Professor, Department of Pediatric Endocrinology, Karolinska Hospital, Stockholm, Sweden

Barbara Y. Whitman, PhD, Professor, Department of Developmental Pediatrics, St. Louis University, Cardinal Glennon Children's Hospital, St. Louis, Missouri, USA

*In 2003, a warning label was added to Genotropin/Genotonorm (Pfizer), the growth hormone preparation labeled for treatment of PWS. The warning label includes recommendations for evaluation of sleep and breathing disorders and screening for morbid obesity prior to initiation of therapy. The Clinical Advisory Board of the Prader-Willi Syndrome Association (USA) subsequently issued its own guidelines regarding sleep, breathing, and respiratory evaluation. These subjects are discussed extensively in Chapters 5 and 7 of this volume and are not specifically addressed in the Comprehensive Care guidelines.

Panelists:

Giuseppe Chiumello, MD, Professor, Università degli Studi di Milano, Clinica Pediatrica III Ospedale San Raffaele, Milan, Italy

Yukihiro Hasegawa, MD, Chief, Endocrinology, Metabolism and Genetics Unit, Tokyo Metropolitan Kiyose Children's Hospital, Tokyo, Japan

Priv-Doz Dr med Berthold P. Hauffa, Abt. F. pädiatrische Hämatologie/Onkologie und Endocrinologie, Universität GHS Essen, Essen, Germany

Maïthé Tauber, MD, Professor, Children's Hospital Toulouse, Toulouse, France

Introduction

The treatment of children with Prader-Willi syndrome (PWS) represents a challenge, particularly in the field of pediatric endocrinology. The handicaps and problems of affected children are manifold, more so than in any other typical disease of pediatric endocrinology, perhaps with the exception of craniopharyngioma. Therefore, management of children with PWS may be most successful with a team approach to comprehensive care. We thank Pharmacia Corporation for organizing a workshop on such an approach in St. Julians, Malta, on April 24, 2001.

The reader will notice that the development of a comprehensive professional team approach to PWS has only just begun. Much work remains to be done, primarily to define what, exactly, a "comprehensive team approach" to PWS means. For example, it appears necessary for one highly experienced specialist team member to assume leadership, to allow patients and their families to interact with one single professional. Furthermore, growth hormone (GH) treatment has become a very important tool in the management of PWS. Nevertheless, it must be emphasized that without a comprehensive team approach, especially to control weight gain, optimize dietary intake, and provide family psychosocial support, children with PWS may continue to suffer from excessive weight gain and major behavioral problems despite the beneficial effects of GH.

Some centers have a great deal of experience and know-how in managing PWS. This know-how, however, is most often attributable to the experience of a single person. Through intensive study of the experience and strategies of such centers and individuals, a professional comprehensive team approach can be developed that will allow centers all over the world to offer optimum care to their patients with PWS.

Prader-Willi syndrome (PWS) is characterized by infantile hypotonia; short stature; small hands and feet; increased body fat; decreased muscle mass; scoliosis; reduced resting energy expenditure (REE); reduced bone mineral density (BMD), which may lead to osteopenia and osteoporosis; hypogonadism; hypothalamic dysfunction; and a particular facial appearance. These clinical features are accompanied by hyperphagia, cognitive disabilities, and behavioral problems, including skin picking. In approximately 70% of affected individuals, the

syndrome is the phenotypic expression of a complex genetic disorder resulting from a de novo deletion of the “PWS region” located on the proximal long arm of the paternal copy of chromosome 15 (at bands 15q11.2–15q13). Maternal disomy 15 (inheritance of both chromosome 15 copies from the mother, with no paternal copy) is seen in about 25% of individuals with PWS. Chromosomal translocations involving the paternal “PWS region” of 15q and imprinting center defects account for a small percentage of cases.¹ Prader-Willi syndrome and Angelman syndrome (an entirely different clinical syndrome involving defects in the maternal copy of 15q) were among the first examples in humans of genomic imprinting, or the differential expression of genetic information depending on the parent of origin. Prader-Willi syndrome is one of the more common conditions seen in genetics clinics worldwide, occurring in an estimated 1:10,000–25,000 individuals, and is the most common syndrome associated with morbid or life-threatening obesity. For affected individuals, the various clinical manifestations of PWS are major causes of morbidity and social limitation. Learning ability, speech and language, self-esteem, emotional stability, social perception, interpersonal functioning, and family dynamics, in addition to cognition and behavior, are all adversely affected in PWS.

A panel of international experts on PWS was convened to share their clinical experience and to identify strategies for managing PWS. The panel agreed that, because PWS produces various adverse functional as well as metabolic effects, individuals with PWS require a variety of interventions to optimize their growth and development. These include growth hormone (GH) replacement; dietary management; physical and occupational therapy; speech, language, and learning disability services; behavior management; and family interaction, support, and care. Children with PWS should be evaluated and treated in a multidisciplinary clinic that is managed by a nurse coordinator and staffed by a physician specialist in PWS, geneticist, psychologist, and dietitian. Ancillary resources should include support by neurology, physical therapy, social services, and educational services, as well as readily available facilities for measuring body composition (including whole-body DEXA) and exercise physiology. The Table (B.1) lists the components of the initial evaluation and testing. Follow-up visits are recommended at 6-month intervals for patients receiving GH therapy. In the majority of patients puberty will not occur, and gonadal steroid replacement therapy should be considered for them on the basis of clinical and DEXA findings.

GH Effects on Physical Parameters in PWS

Dysregulated GH secretion associated with deficient GH responses is a principal cause of short stature in the majority of individuals with PWS. It is probably also an important contributor to the decreased muscle mass and osteopenia in patients with PWS, whereas hypogonadotropic hypogonadism is the probable primary cause of osteopenia and osteoporosis in these patients.² Evidence is mounting that GH

Table B.1. Recommended Components of the Initial Visit to a Multidisciplinary Prader-Willi Syndrome Clinic**Evaluation**

- Confirmation of diagnosis, genetic counseling
- Complete examination
- Dietary evaluation and counseling
- Physical therapy evaluation (developmental, neuromuscular)
- Psychological evaluation and recommendations
- Educational evaluation and recommendations
- Initial discussion of growth hormone therapy and approval process

Testing

- DNA studies
- IGFBP-3, IGF-I, thyroid panel, lipid panel (other lab tests as clinically indicated)
- Screening for glucose intolerance if patient is obese (fasting glucose, glycated hemoglobin, oral glucose tolerance test, if indicated)
- Body composition analysis (DEXA, anthropometry, or other method)
- Psychological and/or educational testing
- Strength and endurance testing

DEXA = dual-energy X-ray absorptiometry; IGF-I = insulin-like growth factor-I; IGFBP-3 = IGF binding protein-3.

deficiency may contribute not only to the abnormal growth pattern but also to the excess of body fat and the lean body mass deficit.^{3,4} Growth hormone treatment of children with PWS normalizes linear growth,⁵⁻¹⁰ promotes growth of lean body mass,^{6-8,11,12} and decreases fat mass.^{6-8,11,12} However, the benefits associated with GH therapy can be optimized and maintained only in conjunction with a multidisciplinary approach that emphasizes comprehensive care for the complex neurobehavioral and endocrine needs appropriate for the patient's age.

The role of GH as a component of the overall management of PWS has been studied extensively in the United States, Switzerland, and Sweden.

American Experience

Parra and co-workers observed in 1973 that a deficient GH response to pharmacologic stimuli appeared to be related to the abnormal growth pattern in patients with PWS.¹³ In 1987, Lee and colleagues reported for the first time that GH therapy led to significant increases in the linear growth rate of patients with PWS.⁶ Patients in their study initially had low serum levels of GH and insulin-like growth factor-I (IGF-I); during GH therapy, levels of IGF-I normalized. These results indicated that the low GH levels observed in these cases were not an artifact of obesity and supported the premise that the poor linear growth in patients with PWS might be caused by a true deficiency of GH. In 1993, Lee and collaborators reported the results of an uncontrolled trial of GH therapy in 12 obese children with PWS and associated chromosome 15 abnormalities.¹⁴ All 12 children initially had low serum levels of GH, IGF-I, IGF-2, IGF binding protein-3 (IGFBP-3), and osteocalcin. These levels normalized and height velocity increased during GH therapy. Dual-energy X-ray absorptiometry (DEXA) at baseline revealed in-

creased fat mass, normal (not weight-corrected) BMD, and very low lean body mass. Within 3 months of the patients' beginning GH therapy, DEXA revealed variable changes in fat mass and increased BMD and lean body mass, with redistribution of fat mass from the trunk to the thighs. The majority of parents reported improved behavior and appetite control. The decreased GH secretion commonly seen in children with PWS had been considered by some to be an effect of obesity, but reduced GH secretion had also been found in non-obese children with PWS.

Angulo and colleagues studied 33 obese and 11 non-obese children with PWS to determine whether the suboptimal GH secretion was an artifact of obesity.¹⁵ Spontaneous GH secretion was measured over 24 hours, and GH secretion was provoked by insulin, clonidine, and levodopa. Of the 44 subjects, 40—including 10 non-obese children—failed to respond to at least two of the stimuli, and 43 had reduced spontaneous 24-hour GH secretion. The investigators concluded that the GH deficiency seen in PWS is not a consequence of obesity but rather a significant contributor to the decreased growth velocity and increased adiposity typical of the syndrome.

In a controlled trial reported in 1999, Carrel and associates assessed the effects of GH therapy on growth, body composition, strength and agility, respiratory muscle function, REE, and fat utilization in 54 children with PWS, all of whom had low peak stimulated GH levels at baseline.⁶ Thirty-five children received GH at a dose of 1 mg/m²/day and 19 were untreated. After 12 months, the GH-treated children showed significantly increased height velocity, decreased percentage of body fat, and improved physical strength, agility, and respiratory muscle function, although there was no significant increase in REE. The investigators concluded that GH therapy, in addition to its effect on growth and body composition, may have value in improving some physical disabilities experienced by children with PWS. After 24 months of GH therapy, patients had experienced sustained decreases in fat mass, increases in lean body mass,⁷ and improvements in physical strength and agility.⁸ Height velocity remained significantly higher than at baseline ($P < 0.01$), although the growth rate slowed between 12 and 24 months. To achieve these encouraging results, the investigators suggested, GH therapy should be started early; GH therapy started in middle to late childhood may not be capable of normalizing the percentage of body fat in patients with PWS.⁷

At baseline, 70% of subjects had mild to moderate scoliosis on spine films.⁸ During the first year of the study, no significant difference in scoliosis progression was seen between the GH-treated group (from a mean of 9.2° at baseline to 12.1°) and the control group (from 14.7° to 16.6°). During the second year, the mean change in curve measurement in the GH-treated group also was not significant.

Swiss Experience

Disturbed satiation and energy expenditure are basic defects in PWS. Reduced muscle mass appears to be the consequence of decreased

physical activity, which is probably caused by the central nervous system defects. Reduced muscle mass, in turn, is the cause of the decreased energy requirement. The benefit of GH therapy for children with PWS, according to Eiholzer's group, is an increase in lean body mass and a subsequent increase in REE. If energy intake is not increased, these alterations lead to a reduction of energy stores, mainly of body fat, and a dramatic change in phenotype. However, even though height and weight are normalized during GH treatment, children with PWS must maintain their energy intake at about 75% of the intake of healthy children to stabilize their weight for height. Such a reduction of food intake is possible only through close, strict parental supervision, and this is a major reason why families caring for a child with PWS need psychosocial support. Following is a short summary of the Swiss experience with GH therapy.

Eiholzer and l'Allemand described 23 children with genetically confirmed PWS and divided them into three groups: group 1 comprised young children who were not yet obese; group 2, prepubertal overweight children; and group 3, pubertal overweight children. All were treated with GH 24U/m²/week (~0.037 mg/kg/day) for a median of 4 years (range, 1.5 to 5.5 years).⁹ In group 1, weight and weight for height were lower than normal before treatment and continuously increased up to the normal range during treatment. In group 2, a dramatic height increase and drop in weight for height showed clearly that these obese children had become not only taller but also slimmer with treatment. In group 3, however, the effect of GH on growth and weight was rather limited. The investigators concluded that if treatment is instituted early enough, growth becomes normal and height predictions reach the parental target height. This effect of exogenous GH on growth has so far been described only in children with GH deficiency.

Most importantly, although loss of fat mass, as determined by DEXA,¹² in the older children (group 3) was considerable with exogenous GH administration, fat mass was still in the upper-normal range. The influence of exogenous GH on muscle mass in PWS was found to be limited. Catch-up growth in muscle mass, as estimated by lean mass, was observed only during the first 6 months of therapy; thereafter, muscle mass increased in parallel with height. Therefore, it was deduced that muscle mass remained relatively decreased.

Improvement in body composition is the main goal in the treatment of children with PWS. According to the Swiss experience, the changes in body composition during GH therapy result from several therapeutic interventions. It is critical to maintain control of nutrient intake during GH treatment, in accordance with the reduced energy requirements in PWS. In children with PWS, energy requirements are about 50% below those of healthy children.¹⁷ Growth hormone treatment does not change the feeling of satiety but increases the energy expenditure resulting from the increase of lean mass by an estimated 25%, as shown by another Swiss study.¹⁸ Weight for height and BMI decrease during GH treatment only if energy intake is not increased at the same time. It is therefore imperative that parents continue to keep patients' food

consumption under control with the same rigidity as before the start of GH treatment.

Hypothesizing that increased muscle mass in infants may positively influence motor development, Eiholzer and colleagues used the Griffith test¹⁹ to study psychomotor development in 10 young, underweight children with PWS during the first year of GH treatment.²⁰ At baseline, the children were significantly more retarded on the “locomotor” and “hearing and speech” scales than on the other scales. During GH therapy, locomotor capabilities increased significantly, whereas hearing and speech remained unchanged. The treated children started walking unassisted at an average age of 24.1 months, about 4 to 6 months earlier than untreated children with PWS. Motor development thus seems to be improved by GH therapy.

In older children, improvement in physical performance is—in the opinion of the parents—the most important therapeutic effect of GH.²¹ After 1 year of GH therapy, physical performance, as assessed by ergometry, significantly increased in peak and mean power in four prepubertal 7-year-old obese children. Such improvement in physical performance leads to an increase in activity, which, together with the disappearance of the obese phenotype, may relieve patients and their families of a major stigma that accompanies PWS, improving their quality of life.

The Swiss group was also able to show for the first time that insulin secretion in children with PWS is delayed and lower than that shown in otherwise normal, nonsyndromal obese children and in children without PWS on GH therapy.²² In addition, the increase in fasting insulin and insulin resistance seen in children with PWS during GH therapy is transient.²² Three years of GH therapy did not impair carbohydrate metabolism, but rather counteracted the potential GH-induced insulin resistance by decreasing fat mass and increasing lean mass. Since normal insulin sensitivity remains preserved, the investigators speculated that the primary mechanism for the development of diabetes in PWS is a reduced secretory capacity of pancreatic beta cells that persists despite GH administration.

According to the Swiss researchers, certain aspects of lipid metabolism differ in PWS and non-PWS obesity. In PWS, triglyceride levels are normal (although still correlated with abdominal obesity), but LDL cholesterol levels are elevated and HDL cholesterol levels are decreased.²³ These lipid levels normalize during GH therapy, but the changes are not associated with changes in body fat and probably are caused by the direct effects of GH deficiency and exogenous GH administration on cholesterol metabolism, as described in adult patients with GH deficiency.²⁴

Swedish Experience

Despite the evidence from uncontrolled trials that GH therapy is beneficial in PWS, a number of pediatric endocrinologists continued to believe that the GH deficiency seen in the syndrome was a result of the characteristic obesity, and they were concerned that treatment with

exogenous GH would negatively affect endogenous GH secretion. For this reason, a controlled study was conducted to assess the effects of GH therapy on growth, body composition, and behavior in prepubertal children with PWS.

Lindgren and co-workers reported preliminary results²⁵ of this study in 1997 and 5-year results¹⁰ in 1999. After a 6-month evaluation period, patients with PWS between the ages of 3 and 7 years were randomized into group A (n = 15), which received GH 0.1 IU/kg/day (0.033 mg/kg/day) for 2 years, or group B (n = 12), which received no treatment for the first year and GH 0.2 IU/kg/day (0.066 mg/kg/day) during the second year. After 2 years, all children stopped GH therapy for 6 months and then restarted GH therapy at a dose of 0.1 IU/kg/day (0.033 mg/kg/day). The 6-month GH-free interval was included to prove that the effects of GH therapy were reversible and to compare the effects of the low and high doses.

Before GH therapy, all patients had low 24-hour levels of GH and IGF-I and low levels of insulin. During the first year of the study, IGF-I levels increased rapidly to supranormal values in group A (GH therapy) but remained essentially unchanged in group B (no treatment). With respect to growth, height velocity standard deviation scores (SDS) increased from -1.9 to 6.0 during the first year of GH therapy in group A, followed by a lower rate of increase during the second year. In group B, height velocity SDS decreased slightly during the first year of the study (no treatment) but increased rapidly from -1.4 to 10.1 in the second year of the study (GH therapy). When GH therapy was stopped for 6 months, height velocity declined dramatically in both groups; height SDS followed a similar pattern. Growth hormone therapy reduced the percentage of body fat and increased the muscle area of the thigh; isometric muscle strength also increased. In addition, parents reported that GH therapy seemed to have psychological and behavioral benefits, which were reversed after treatment was stopped.

Five-year follow-up data on 18 of the children were published in 1999.¹⁰ Following resumption of GH therapy after the 6-month discontinuation, height SDS again increased. Body mass index SDS stabilized at 1.7 for group A (n = 9) and 2.5 for group B (n = 9). In 16 children, levels of fasting insulin, glucose, and the A_{1c} fraction of glycated hemoglobin remained within normal ranges. The remaining two children developed non-insulin-dependent diabetes mellitus following a rapid weight gain, but glucose homeostasis returned to normal when GH was discontinued. Unpublished 7-year follow-up data show that height has been normalizing with prolonged treatment.

Clinical Management of PWS-Associated Behaviors

By adolescence, behavioral problems characteristically have evolved as a major issue for patients with PWS and their families. Adolescents with PWS have been described as stubborn, impulsive, manipulative, irritable, mood-labile, angry, perseverative, egocentric, demanding,

and prone to rage episodes when frustrated. Transitioning from one activity to another becomes increasingly difficult, and there is a tendency to confuse day with night. Thus, the food-related behavior constellation, although dramatic, is just one of many neurobehavioral abnormalities characterizing this disorder, and the food behavior often is the easiest to manage.

These behavioral traits are frequently accompanied by depression, obsessions, or even frank psychoses, and they ultimately are responsible for the inability of adults with PWS to succeed in alternative living and work placements. Interestingly, many of the characteristic behaviors of patients with PWS, including cognitive rigidity, hoarding behavior, impaired judgment, denial of deficits, inability to self-monitor behavior, and interpersonal conflicts, are also seen in patients with traumatic brain damage. In patients with PWS, however, the brain damage is genetic and, unlike traumatic brain damage, appears to affect the entire brain. Prader-Willi syndrome may thus be characterized as a pervasive developmental neurobehavioral syndrome whose behavioral manifestations reflect a distributed central nervous system dysfunction that has yet to be fully described either anatomically or biochemically.

In addition to behavioral problems, four cognitive difficulties have been identified in patients with PWS: global mental retardation, language processing problems, learning disability associated with short-term memory and sequencing deficits²⁷ and failure to develop the ability to apply knowledge in new situations (metacognitive ability). Most patients with PWS score between 60 and 80 on IQ tests, and at least some have IQ scores in the 90s or somewhat higher. Functional aptitude, however, is entirely independent of test scores and appears to be related more to the degree of cognitive rigidity. Impaired metacognitive ability prevents patients with PWS from utilizing their typically extensive compendium of facts in a practical or productive manner. Difficulty with sequencing and language deficits underlies most of the behavioral problems and the inability to change some behaviors. Sequencing difficulty extends beyond simple numerical applications and includes an inability to recognize cause-and-effect sequences. This particular problem necessitates an entirely different approach to traditional behavior management, since patients with PWS fail to link punishment or reward with an antecedent behavior.

Many patients with PWS who frequently exhibit problem behaviors are able to alter these behaviors when environmental changes are instituted. These changes require creativity, hard work, and, often, many months before a behavior is altered, and some environmental and family situations are unalterable. It is particularly difficult when parents disagree about the management approach. Children with PWS who have the worst behavior in terms of depression and anxiety come from families in which parents report the highest level of conflict over child rearing. Although this is also true for normal children, children with PWS do not have the flexibility seen in normal children. Therefore, family therapy is recommended as soon as the diagnosis of PWS is made in an infant or young child.

For many patients with PWS, problem behaviors are resistant to most attempts at behavioral management, and pharmacologic interventions are often considered when this becomes clear. Unfortunately, psychopharmacologic agents frequently worsen problem behaviors in these individuals. A survey of parents of children with PWS conducted between 1989 and 1993 revealed that almost every available psychotropic agent had been prescribed to manage behavioral problems.^{28,29} Most agents either were ineffective or increased the occurrence of targeted symptoms; only three—haloperidol, thioridazine, and fluoxetine—were effective.³⁰ More recently, it has been found that all serotonin specific reuptake inhibitors seem to have a nonspecific behavior-stabilizing effect, characterized by fewer outbursts, a marked reduction in irritability, and less perseveration, but with no specific antidepressant effect.³¹ Other psychotropic drugs, such as the antipsychotic agent olanzapine and the anticonvulsant agent divalproex sodium, may have an effect.³¹ It must be emphasized, however, that any single agent may produce a dramatically beneficial response in some patients with PWS and a dramatically adverse response in others, and many patients with PWS have idiosyncratic reactions to psychotropic drugs. Those with PWS require only one fourth to one half the standard dose of a psychotropic drug to achieve a benefit; increasing the dose to “normal” often results in toxicity and a return of the problem behavior.³¹ In general, psychotropic medication should be used only when all other interventions, including behavioral modification and environmental changes, have failed.

It should also be noted that appetite-suppressing medications have been ineffective in controlling food-seeking behavior and overeating.¹ Pharmacologic agents, including the amphetamines and agents that block nutrient absorption, which are often effective for weight control in non-PWS obese population, do not appear to alter the brain signals, or perhaps peripheral signals, that drive patients with PWS to seek food and overeat. Until a medication is discovered that can accomplish this goal, good management depends entirely on environmental control, protection against overeating, and an understanding caregiver who recognizes that the constant feeling of hunger experienced by these patients underlies some of their irritability and other behavior characteristics.

With regard to the effect of GH therapy on PWS behavior in the setting of behavioral difficulties and refractoriness to psychopharmacologic agents, surveys of parents indicate that some behaviors improve and none deteriorate.^{26,32} Since the behavior of children with PWS tends to deteriorate over time, the absence of deterioration is, in fact, a positive outcome. Specific behavioral benefits of GH therapy, as reported anecdotally by parents, included increased energy, increased activity without the need for encouragement, improved personal hygiene, less “annoying” behavior, increased assumption of responsibility, and less perseveration.^{26,32} In addition, attention span and compliance seemed to improve and anxiety, depression, and obsessive thoughts decreased, although there was no impact on obsessive-compulsive behavior or improvement in school performance. Growth hormone therapy also

produced positive effects on physical appearance, usually within 3 to 6 months of patients' starting treatment. Appearance of the hands, feet, and trunk normalized in all GH recipients, and appearance of the head normalized in 81%. Such changes may positively affect patients' social interaction. Furthermore, 97% of patients had more energy and 83% spontaneously increased their level of physical activity without parental prodding.

Improving Quality of Life in Patients with PWS: Diet, Exercise, and Lifestyle Changes

Surveys performed in the United Kingdom in 1989 and 1999 have provided useful information about the impact of lifestyle changes on PWS. From the standpoint of diet, two distinct phases of PWS are apparent: initial failure to thrive and subsequent obesity.

Failure to thrive results primarily from hypotonia, which makes sucking difficult during infancy. Nasogastric tube feeding may be necessary for as long as 2 months to meet energy requirements. Signs of poor feeding in infants with PWS include changes in the voice or cry, coughing while swallowing, excessive drooling, frequent vomiting, constipation, respiratory infections, irritability during feeding, slow intake, and poor weight gain. For infants who are able to suck, specially designed nipples can reduce the energy expenditure. Early weaning to soft food will reduce energy requirements; introduction of solids is accompanied by a lessening of appetite for milk.³³ However, some 33% of older infants with PWS are unable to eat soft food normally acceptable at 1 year, and children with PWS typically lag far behind children without PWS in their transition to solid food, with 42% of children with PWS unable to chew some solid foods at the age of 5 years.³⁴

The change from failure to thrive to excessive weight gain generally occurs between 2 and 4 years; there seems to be a recent shift toward the younger age. Despite their reduced energy requirement, these children are obsessed with food and engage in food seeking and food stealing. Overeating may be due to the prolonged eating drive that results from their disturbed feelings of satiety.³⁵ The vast majority of parents of children with PWS have attempted to control their children's weight, but dietary compliance is poor. Severe caloric restriction for short periods at home or for longer periods in the hospital setting may be helpful, but most families feel that no intervention will help.

Increased physical activity can increase energy expenditure, promote negative energy balance, raise the post-exercise metabolic rate, build muscle mass, prevent osteoporosis, improve scoliosis, and enhance the overall sense of well-being. However, very few patients with PWS seem to participate in a structured exercise program. Aerobic exercise, toning and strengthening, flexing and stretching, and formal physiotherapy are all useful for patients with PWS. Activities they may find acceptable include bicycling, skating, jumping on a trampoline, dancing, and ball playing.

Lifestyle changes that can be implemented certainly include control of food-seeking and food-stealing behaviors but also must encompass social integration and independence. Specific environmental controls designed to limit hyperphagia include locking places where food is stored, restricting access to money or credit cards, and prohibiting participation in food preparation. Unfortunately, many of these impositions and limitations may actually discourage social integration and independence.

Summary and Conclusion

Because of its many physical and behavioral manifestations, PWS should be managed in a multidisciplinary setting that emphasizes comprehensive care. Clinical trials confirm that GH treatment of children with PWS normalizes linear growth, promotes an increase in lean body mass, and decreases fat mass. However, due to the complex nature of the syndrome, the long-term benefits of GH can be optimized and maintained only in conjunction with dietary control and counseling, physical therapy, and psychological and educational evaluation and support.

References

1. Butler MG, Thompson T. Prader-Willi syndrome: clinical and genetic findings. *The Endocrinologist*. 2000;10(suppl 1):3S-16S.
2. Lee PDK. Effects of growth hormone treatment in children with Prader-Willi syndrome. *Growth Hormone and IGF Research*. 2000;10(suppl B):S75-S79.
3. Eiholzer U, Bachmann S, l'Allemand D. Growth hormone deficiency in Prader-Willi syndrome. *The Endocrinologist*. 2000;10(suppl 1):50S-56S.
4. Eiholzer U, Bachmann S, l'Allemand D. Is there growth hormone deficiency in Prader-Willi syndrome? Six arguments to support the presence of hypothalamic growth hormone deficiency in Prader-Willi syndrome. *Hormone Research*. 2000;53(suppl 3):44-52.
5. Lee PDK, Wilson DM, Rountree L, Hintz RL, Rosenfeld RG. Linear growth response to exogenous growth hormone in Prader-Willi syndrome. *American Journal of Medical Genetics*. 1987;28:865-871.
6. Carrel AL, Myers SE, Whitman BY, Allen DB. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: a controlled study. *Journal of Pediatrics*. 1999;134:215-221.
7. Carrel AL, Myers SE, Whitman BY, Allen DB. Prader-Willi syndrome: the effect of growth hormone on childhood body composition. *The Endocrinologist*. 2000;10(suppl 1):43S-49S.
8. Myers SE, Carrel AL, Whitman BY, Allen DB. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome. *Journal of Pediatrics*. 2000;137:42-49.
9. Eiholzer U, l'Allemand D. Growth hormone normalizes height, prediction of final height and hand length in children with Prader-Willi syndrome after 4 years of therapy. *Hormone Research*. 2000;53:185-192.

10. Lindgren AC, Ritzén EM. Five years of growth hormone treatment in children with Prader-Willi syndrome: Swedish National Growth Hormone Advisory Group. *Acta Paediatrica Supplement*. 1999;433:109–111.
11. Lindgren AC, Hagenäs L, Müller J, et al. Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably. *Acta Paediatrica*. 1998;87:28–31.
12. Eiholzer U, l'Allemand D, van der Sluis I, Steinert H, Gasser T, Ellis K. Body composition abnormalities in children with Prader-Willi syndrome and long-term effects of growth hormone therapy. *Hormone Research*. 2000;53:200–206.
13. Parra A, Cervantes C, Schultz RB. Immunoreactive insulin and growth hormone responses in patients with Prader-Willi syndrome. *Journal of Pediatrics*. 1973;83:587–593.
14. Lee PD, Hwu K, Henson H, et al. Body composition studies in Prader-Willi syndrome: effects of growth hormone therapy. In: Ellis KJ, Eastman JD, eds. *Human Body Composition. In Vivo Methods, Models, and Assessment*. New York, NY: Plenum Press; 1993:201–205.
15. Angulo M, Castro-Magana M, Mazur B, Canas JA, Vitollo PM, Sarrantonio M. Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome. *Journal of Pediatric Endocrinology and Metabolism*. 1996;9:393–400.
16. Boot AM, Bouquet J, de Ridder MA, Krenning EP, deMuinck Kaizer-Schrama SM. Determinants of body composition measured by dual-energy X-ray absorptiometry in Dutch children and adolescents. *American Journal of Clinical Nutrition*. 1997;66:232–238.
17. Stadler DD. Nutritional management. In: Greenswag LR, Alexander RC, eds. *Management of Prader-Willi Syndrome*. New York, NY: Springer-Verlag; 1995:88–114.
18. Eiholzer U. *Prader-Willi Syndrome. Effects of Human Growth Hormone Treatment*. In: Savage MO, ed. *Endocrine Development Series, Vol. 3*. Basel: Karger; 2001:51–54.
19. Brandt I. *Griffiths Entwicklungsskalen zur Beurteilung der Entwicklung in den ersten beiden Lebensjahren*. Weinheim and Basel: Beltz Verlag; 1983.
20. Eiholzer U, Malich S, l'Allemand D. Does growth hormone therapy improve motor development in infants with Prader-Willi syndrome? [letter]. *European Journal of Pediatrics*. 2000;159:299.
21. Eiholzer U, Gisin R, Weinmann C, et al. Treatment with human growth hormone in patients with Prader-Labhart-Willi syndrome reduces body fat and increases muscle mass and physical performance. *European Journal of Pediatrics*. 1998;157:368–377.
22. l'Allemand D, Schlumpf M, Torresani T, Girard J, Eiholzer U. Insulin secretion before and under 3 years of growth hormone (GH) therapy in Prader-Willi syndrome (PWS) [abstract]. *Experimental and Clinical Endocrinology and Diabetes*. 2000(suppl 1);108:127.
23. l'Allemand D, Eiholzer U, Schlumpf M, Steinert H, Riesen W. Cardiovascular risk factors improve during 3 years of growth hormone therapy in Prader-Willi syndrome. *European Journal of Pediatrics*. 2000;159:835–842.
24. Vahl N, Jorgensen JO, Hansen TP, et al. The favourable effects of growth hormone (GH) substitution on hypercholesterolaemia in GH-deficient adults are not associated with concomitant reductions in adiposity. A 12 month placebo-controlled study. *International Journal of Obesity and Related Metabolic Disorders*. 1998;22:529–536.
25. Lindgren AC, Hagenäs L, Müller J, et al. Effects of growth hormone treatment on growth and body composition in Prader-Willi syndrome: a pre-

- liminary report. The Swedish National Growth Hormone Advisory Group. *Acta Paediatrica Supplement*. 1997;423:60–62.
26. Whitman BY, Myers S, Carrel A, Allen D. A treatment/control group study of growth hormone treatment: impact on behavior—a preliminary look. *The Endocrinologist*. 2000;10(suppl 1):31S–37S.
 27. Dykens EM, Hodapp RM, Walsh K, Nash LJ. Profiles, correlates, and trajectories of intelligence in Prader-Willi syndrome. *Journal of the American Academy of Child and Adolescent Psychiatry*. 1992;31:1125–1130.
 28. Whitman BY, Greenswag L. The use of psychotropic medications in persons with Prader-Willi syndrome. In: Cassidy S, ed. *Prader-Willi Syndrome and Other Chromosome 15q Deletion Disorders*. Berlin: Springer Verlag in cooperation with NATO Scientific Affairs Division; 1992:223–231.
 29. Greenswag LR, Whitman BY. Long term follow-up of use of Prozac as a behavioral intervention in 57 persons with Prader-Willi syndrome. Proceedings: 2nd Prader-Willi Syndrome International Scientific Workshop and Conference. 1995 [abstract 20].
 30. Whitman B, Greenswag L. Psychological issues in Prader-Willi syndrome. In: Greenswag L, Alexander R, eds. *Management of Prader-Willi Syndrome*. 2nd ed. New York, NY: Springer Verlag; 1995:125–141.
 31. Whitman B, Greenswag L, Boyt M. The use and impact of psychotropic medications for managing behavior in persons with Prader-Willi syndrome. Proceedings: 13th Annual Prader-Willi Syndrome Association (USA) Scientific Conference. July 22, 1998; Columbus, OH.
 32. Whitman B, Myers S, Carrel A, Allen DB. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a two-year controlled study. *Pediatrics*. 2002;109(2):E35.
 33. Shaw V, Lawson M. Principles of paediatric dietetics. In: Shaw V, Lawson M, eds. *Clinical Paediatric Dietetics*. 2nd ed. Oxford, UK: Blackwell Science; 2001:Chap 1.
 34. Morris M. Feeding the young child with PWS. *The Gathered View*. 1993; 18(1):6–7.
 35. Lindgren AC, Barkeling B, Hagg A, et al. Eating behavior in Prader-Willi syndrome, normal weight, and obese control groups. *Journal of Pediatrics*. 2000;137:50–55.

Appendix C

Growth Charts of Individuals with Prader-Willi Syndrome

Data from the United States

Data in Figures C.1 through C.5 are based on measurements of 71 Caucasian U.S. subjects with PWS between the ages of 0 and 24 years, including 42 males and 29 females, reported by Butler and Meaney. Under high-resolution chromosome analysis, 37 subjects had an apparent chromosome 15 deletion, 26 had normal-appearing chromosomes, and 8 had an unknown chromosome status. Approximately half of the subjects were on a calorie-restricted diet, and none were treated with growth hormone. No significant differences were found between those with a chromosome deletion and those with normal-appearing chromosomes, but there were significant variations by gender.

Data source: Butler MG, Meaney FJ. Standards for selected anthropometric measurements in Prader-Willi syndrome. *Pediatrics*, 1991;88(4):853–860. Reproduced by permission of *Pediatrics*, 1991;88:853–858. (Charts were modified by Dr. Merlin Butler to add standard measure equivalents to the original metric units.)

Data from Germany

Data in Figures C.6 and C.7 are based on measurements of 100 subjects of German descent between the ages of 0 and 20 years, including 51 males and 49 females, reported by Hauffa et al. All subjects had genetically confirmed PWS by molecular genetics testing; 76 had deletions, 14 had maternal uniparental disomy, 3 had imprinting mutations, and 7 were of undetermined molecular class. None of the subjects had received a growth-promoting therapy. In comparison with the U.S. data described above, the researchers found that “Height centile curves of the German patients fall in the tall range of standards derived from American patients . . . mainly due to an elevation of the lower centile ranges in both sexes.” They also found that after age 14 “German girls with PWS are heavier than their American counterparts.”

Data source: Dr. Berthold P. Hauffa provided combination height and weight charts based on PWS data reported in Hauffa BP, Schlippe G, Roos M, Gillessen-Kaesbach G, Gasser T. "Spontaneous growth in German children and adolescents with genetically confirmed Prader-Willi syndrome." *Acta Paediatrica*, 2000;89:1302–1311. These modified clinical charts were prepared by Pharmacia Corporation, substituting German reference data for the Dutch reference data in the original article. Reprinted with English labels by permission of Pharmacia Corporation.

Data from Japan

Data in Figures C.8 through C.15 are based on measurements of 252 Japanese individuals with PWS between the ages of 0 and 24 years, including 153 males and 99 females, reported by Nagai et al. The subjects were diagnosed with PWS by clinical, cytogenetic, and/or molecular genetic methods; 198 were found to have a chromosome 15q abnormality (deletion), 26 had maternal uniparental disomy, and in 28 no chromosome analysis was available. Approximately one third of the subjects were on a calorie-restricted diet. The researchers found that "Growth patterns are not different between Japanese and Caucasian children with the syndrome" but that "the degree of overweight appears much more severe in Caucasians."

Data source: Nagai T, Matsuo N, Kayanuma Y, et al., Standard growth curves for Japanese patients with Prader-Willi syndrome," *American Journal of Medical Genetics*, 2000;95:130–134. Original growth charts from this report, courtesy of Dr. Toshiro Nagai, are reprinted with permission of Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc.




Figure C.1. Data from USA. Standardized curves for height of Prader-Willi syndrome (PWS) male and female patients (solid line) and healthy individuals (broken line). Modified from Butler and Meaney, 1991. Reproduced by permission of *Pediatrics*, Vol. 88, p. 854, Copyright © 1991.




Figure C.2. Data from USA. Standardized curves for weight of Prader-Willi syndrome (PWS) male and female patients (solid line) and healthy individuals (broken line). Modified from Butler and Meaney, 1991. Reproduced by permission of *Pediatrics*, Vol. 88, p. 853, Copyright © 1991.




Figure C.3. Data from USA. Standardized curves for head circumference of Prader-Willi syndrome (PWS) male and female patients (solid line) and healthy individuals (broken line). Modified from Butler and Meaney, 1991. Reproduced by permission of *Pediatrics*, Vol. 88, p. 855, Copyright © 1991.




Figure C.4. Data from USA. Standardized curves for hand length of Prader-Willi syndrome (PWS) male and female patients (solid line) and healthy individuals (broken line). Modified from Butler and Meaney, 1991. Reproduced by permission of *Pediatrics*, Vol. 88, p. 856, Copyright © 1991.




Figure C.5. Data from USA. Standardized curves for foot length of Prader-Willi syndrome (PWS) male and female patients (solid line) and healthy individuals (broken line). Modified from Butler and Meaney, 1991. Reproduced by permission of *Pediatrics*, Vol. 88, p. 858, Copyright © 1991.




Figure C.6. Data from Germany. Centile curves (5th, 25th, 50th, 75th, 95th centile) for length/height (top) and for weight (bottom) of male German PWS patients, compared with reference growth standards of normal children (shaded area representing the 3rd to 97th centile range). Modified clinical chart based on Hauffa et al., *Acta Paediatrica*, 2000, Vol. 89, pp. 1302–1311. Reprinted with permission from Pharmacia Corp. Chart courtesy of Dr. Berthold P. Hauffa.




Figure C.7. Data from Germany. Centile curves (5th, 25th, 50th, 75th, 95th centile) for length/height (top) and for weight (bottom) of female German PWS patients, compared with the reference growth standards of normal children (shaded area representing the 3rd to 97th centile range). Modified clinical chart based on Hauffa et al., *Acta Paediatrica*, 2000, Vol. 89, pp. 1302–1311. Reprinted with permission from Pharmacia Corp. Chart courtesy of Dr. Berthold P. Hauffa.

Length in PWS Males




Figure C.8. Data from Japan. Body length of male Japanese PWS patients from birth to age 24 months. Solid lines show 3rd, 50th, and 97th centile values for PWS patients, and dotted lines 3rd and 97th centile values for normal children. From Nagai et al., *American Journal of Medical Genetics*, Vol. 95, p. 131, Copyright © 2000. Reprinted with permission of Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc. Chart courtesy of Dr. Toshiro Nagai.

Length in PWS Females




Figure C.9. Data from Japan. Body length of female Japanese PWS patients from birth to age 24 months. Solid lines show 3rd, 50th, and 97th centile values for PWS patients, and dotted lines 3rd and 97th centile values for normal children. From Nagai et al., *American Journal of Medical Genetics*, Vol. 95, p. 131, Copyright © 2000. Reprinted with permission of Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc. Chart courtesy of Dr. Toshiro Nagai.

Height in PWS Males




Figure C.10. Data from Japan. Height of male Japanese PWS patients from ages 2 to 17 years. Solid lines show 3rd, 50th, and 97th centile values for PWS patients, and dotted lines 3rd and 97th centile values for normal children. From Nagai et al., *American Journal of Medical Genetics*, Vol. 95, p. 132, Copyright © 2000. Reprinted with permission of Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc. Chart courtesy of Dr. Toshiro Nagai.

Height in PWS Females




Figure C.11. Data from Japan. Height of female Japanese PWS patients from ages 2 to 17 years. Solid lines show 3rd, 50th, and 97th centile values for PWS patients, and dotted lines 3rd and 97th centile values for normal children. From Nagai et al., *American Journal of Medical Genetics*, Vol. 95, p. 132, Copyright © 2000. Reprinted with permission of Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc. Chart courtesy of Dr. Toshiro Nagai.

Weight in PWS Males




Figure C.12. Data from Japan. Body weight of male Japanese PWS patients from birth to age 24 months. Solid lines show 3rd, 50th, and 97th centile values for PWS patients, and dotted lines 3rd and 97th centile values for normal children. From Nagai et al., *American Journal of Medical Genetics*, Vol. 95, p. 133, Copyright © 2000. Reprinted with permission of Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc. Chart courtesy of Dr. Toshiro Nagai.

Weight in PWS Females




Figure C.13. Japanese Data. Body weight of female Japanese PWS patients from birth to age 24 months. Solid lines show 3rd, 50th, and 97th centile values for PWS patients, and dotted lines 3rd and 97th centile values for normal children. From Nagai et al., *American Journal of Medical Genetics*, Vol. 95, p. 133, Copyright © 2000. Reprinted with permission of Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc. Chart courtesy of Dr. Toshiro Nagai.

Weight in PWS Males




Figure C.14. Japanese Data. Body weight of male Japanese PWS patients from ages 2 to 17 years. Solid lines show 3rd, 50th, and 97th centile values for PWS patients, and dotted lines 3rd and 97th centile values for normal children. From Nagai et al., *American Journal of Medical Genetics*, Vol. 95, p. 133, Copyright © 2000. Reprinted with permission of Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc. Chart courtesy of Dr. Toshiro Nagai.

Weight in PWS Females




Figure C.15. Japanese Data. Body weight of female Japanese PWS patients from ages 2 to 17 years. Solid lines show 3rd, 50th, and 97th centile values for PWS patients, and dotted lines 3rd and 97th centile values for normal children. From Nagai et al., *American Journal of Medical Genetics*, Vol. 95, p. 133, Copyright © 2000. Reprinted with permission of Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc. Chart courtesy of Dr. Toshiro Nagai.

Appendix D

Eligibility for U.S. Social Security and SSI Benefits for Individuals with Prader-Willi Syndrome

Barbara R. Silverstone, Staff Attorney, National Organization of Social Security Claimants' Representatives

If your child suffers from a chronic condition such as Prader-Willi syndrome, you may have concerns about affording the care he currently needs and his well-being when you are no longer able to support him. If your child is sufficiently disabled and will be unable to work, you need more information about the disability benefits programs administered by the U.S. Social Security Administration (SSA).

The Social Security Administration administers two types of programs for disabled individuals: Social Security Disability Insurance (SSDI), also known as Title II and DIB, and Supplemental Security Income, also known as SSI and Title XVI. Although they have the same definition of disability, there are different requirements for each benefit program.

Social Security Disability Insurance is paid to adults who become disabled and who have a sufficient work history. SSDI also provides income for their dependents. Dependents include their minor children, disabled adult children, and sometimes their spouse. Medicare coverage is available after the disabled individual has received benefits for 2 years. The other benefit, SSI, is means-tested. These benefits are paid to disabled adults who have limited income and resources (most adults with Prader-Willi syndrome receive SSI) and to disabled children whose parents have limited income and resources. Due to the "deeming" of parents' income and resources to minor children, children can receive SSI benefits only if their parents have limited income and resources. Medicaid coverage is available upon receipt of SSI benefits. Many people receive benefits under both the SSI and Medicaid programs. There are special rules for SSI eligibility for noncitizens. If you are not a U.S. citizen, contact your attorney or SSA for more information.

An important benefit to be aware of is called Disabled Adult Children's (DAC) benefits. If a child is unmarried and his disability has

continued uninterrupted since before his 22nd birthday, and one of his parents is either retired, disabled, or has died after working enough quarters to qualify as insured, he may be eligible for Social Security disability benefits. Disabled Adult Children's benefits are available to your child even if he or she has never worked and can be used to support a disabled individual whose parents are no longer able to do so. Although these benefits are called "children's" benefits, they are paid to the adult child of a former wage earner. When a recipient of DAC benefits marries, these benefits will end. If you think your child may be eligible for this benefit, you should contact the Social Security Administration for an application. Visit a local office or call 1-800-772-1213. For a referral to a private attorney who is familiar with these benefits, you can call the National Organization of Social Security Claimants' Representatives at 1-800-431-2804.

Determining Eligibility

Social Security Disability Insurance benefits are available to disabled workers who meet two conditions: (1) they are too disabled to work at *any* job, not just the jobs which they held in the past; and (2) through their employment, they have contributed enough FICA tax over the years to be covered. In general, workers who have worked at least 5 out of the 10 years just before the disability began are covered; the rules are different for workers under age 30. An individual's wage history determines the monthly benefit amount.

Remember, even an individual who has not worked, but whose disability began before age 22, may be eligible for Social Security disability benefits, as a Disabled Adult Child.

Supplemental Security Income (SSI) benefits are available to disabled individuals whose income and resources are very limited. Generally, to be eligible for SSI benefits, an individual may have no more than \$2,000 in resources (\$3,000 for a couple) and income that is less than the SSI benefit amount (\$579 per month for an individual and \$869 for a couple in January 2005). The income levels change slightly each year. There are several items, such as a primary residence, car, and certain income, that SSA will not count. Income and resources from a spouse or the parents of a minor child are deemed available to the claimant. Parents' income will be deemed to a minor child even if he or she resides at a school, if the parent has parental control (guardianship) over the child.

Claimants who are eligible for Social Security disability benefits but whose payment amount is very low may also be eligible for SSI benefits.

Who Is "Disabled"?

Eligibility for benefits depends on a child's limitations resulting from physical, mental, and behavioral impairments. SSA decides whether a child has been, or is expected to be, disabled for at least 12 months. The

SSA definition of disability for a child is: “An individual under the age of 18 shall be considered disabled for purposes of this title if that individual had a medically determinable physical or mental impairment which results in marked and severe functional limitations, and which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months.”

Eligibility for disability benefits depends on the limitations an individual has as a result of *both* physical and mental impairments. For example, SSA will consider the effects of obesity on the individual’s heart and ability to walk, as well as other conditions it may cause, such as diabetes or sleep apnea. SSA will also consider mental limitations, including IQ scores and limitations in social functioning and activities of daily living and maladaptive behavior. For example, temper tantrums, obsessive-compulsive behavior, frustration, and need for routine can limit available jobs and can be a “marked and severe functional limitation” in a child’s case.

SSA follows a Sequential Evaluation Process to determine whether a claimant meets the disability criteria. For children, the sequential evaluation is a three-step process:

1. Is the child working?
2. Does the child have a medically determinable impairment or combination of impairments that is severe?
3. Does the child’s impairment meet or medically equal the requirements of a listed impairment; or are the functional limitations caused by the impairment(s) the same as the disabling functional limitations of any listing, and therefore, functionally equivalent to that listing?

If the child is not working, SSA will compare the child’s condition to its criteria in the “Listings of Impairments.” There are several different listings under which an individual with Prader-Willi syndrome may be evaluated.

One listing that SSA may refer to is section 110.00, Multiple Body Systems. Those impairments that SSA classifies as “multiple body systems” are “life-threatening catastrophic congenital abnormalities and other serious hereditary, congenital, or acquired disorders that usually affect two or more body systems” and are expected to either produce long-term significant interference with age-appropriate major daily activities or result in early death. SSA will find a child disabled who suffers from multiple body dysfunction due to any confirmed hereditary, congenital, or acquired condition with either persistent motor dysfunction; significant interference with communication due to speech, hearing, or visual impairments; or mental, growth, or cardiac impairments.

SSA may also evaluate a child with Prader-Willi syndrome under the listings for mental disorders, section 112.00. These listings provide specific requirements for each age group. The conditions in this section that are most likely to be present in a child with Prader-Willi syndrome include: organic mental disorders (112.02); mood disorders (112.04); mental retardation (112.05); anxiety disorders (112.06); somatoform, eating, and tic disorders (112.07); pervasive developmental disorders

(112.10); or developmental and emotional disorders of newborn and younger infants (112.12).

If your child's condition precisely meets any of these criteria, SSA will find that he is disabled. But meeting these criteria is not the only way to qualify for benefits. Even if your minor child does not have the exact test results required, SSA will continue to evaluate the claim by determining whether his or her impairments cause the same type of limitations as any of the listings (medically or functionally equal the listing). Keep in mind that your child's disability can be based on a combination of several impairments that may not be disabling when considered separately, but when evaluated together show that he cannot work.

Functional equivalence is shown when the impairment or a combination of impairments causes the same disabling functional limitations as those of a listed impairment. SSA recognizes that some impairments or combination of impairments can be just as disabling even if the impairment itself is not the same as a listed impairment. SSA will also consider other factors such as the effect of medications, or the effects of structured settings, and school attendance. SSA may recognize that your child functions well in his supportive, special class in school or with the family and friends he knows, but may not be able to function well in an unknown setting or without constant support and supervision.

Although there is no longer a listing for obesity, SSA will also rely on the guidance found in Social Security Ruling 02-1p, which explains how obesity can affect an individual's musculoskeletal, cardiovascular, and respiratory systems.

Remember that SSA reviews and sometimes changes the specific requirements of any listing. Be sure you are relying on the current listing when gathering the necessary medical evidence.

SSA will consider the combined effects of all impairments to determine if the child is disabled under this category. Although an individual's physical or mental impairments considered independently may not be found to be disabling, when SSA considers the combined effect of all impairments, the condition can be functionally equal to a listed impairment.

Claimants over 18 years old are evaluated under adult standards. The adult listing for Multiple Body Systems (Section 10.00) is currently limited to Down syndrome, but this listing explains that SSA will evaluate "other chromosomal abnormalities [that] produce a pattern of multiple impairments but manifest in a wide range of impairment severity . . . under the affected body system." An adult can also be evaluated under the adult listings for Mental Disorders (Section 12.00) and Social Security Ruling 02-1p. As in a child's claim, SSA will consider the combined effect of all impairments on the individual's ability to work.

An adult whose condition does not meet the exact criteria, or who does not have the exact test results required may still be found disabled. SSA will continue to evaluate the claim by considering vocational factors (age, educational background, and work history) along with physical and mental residual functional capacities to decide

whether a claimant is disabled or whether there are jobs that he can do.

What Can You Do to Help Show SSA That You Are Disabled?

SSA will rely on the results of medical tests to determine whether your child can be found disabled, so it is important that he or she has been properly examined by a doctor. SSA wants to see that a doctor has laboratory tests, including chromosomal analysis, where appropriate, and has diagnosed your child with Prader-Willi syndrome. In addition to medical tests, SSA will consider the opinions of the treating physicians, the child's parents, and teacher's notations in school records. Both adults and children can assist their claim by keeping a diary documenting symptoms and how these symptoms affect the ability to function during a typical day.

You can also provide the Administrative Law Judge (ALJ) with medical information about Prader-Willi syndrome *before your hearing*, so the ALJ can be familiar with the nature of the condition. The Prader-Willi Syndrome Association has valuable information that can be provided to the ALJ. (See Appendix F.)

Applying for Benefits

Application forms for disability benefits from the Social Security Administration are obtainable by calling 1-800-772-1213. When the forms are complete, application for both Social Security Disability Insurance and SSI benefits can be filed at any Social Security office. Some people can also apply online at www.socialsecurity.gov/apply-forbenefits. It is important to complete the form with as much information as possible. Give the full names and addresses of all doctors, and the dates of any hospitalizations. Make a list of the medications or other treatments used, their side effects, and any medications and treatments which have been tried but which no longer work. Describe the child's daily activities, and mention whether his/her behavior or weight prevent him from performing certain activities. Tell the child's doctors that he/she is applying for disability benefits, and that the doctor should expect to receive a request for more information from SSA. Many claimants wait until a hearing is scheduled before hiring an attorney to represent them, but you can choose to be represented at any stage of the application process.

Application and Appeals Process

Only about 30% of disability applications will be approved at the first step of the process. If your application is initially denied, there are several steps in the appeal process.

When your claim is denied initially, you should appeal by completing a reconsideration form. You have 60 days to request reconsideration. A different person from SSA will evaluate your claim. You may have to wait a year before you receive a decision at this stage.

You should be aware that SSA is experimenting with eliminating the reconsideration step. Therefore, in some parts of the country, instead of requiring reconsideration of a denial, you would request a hearing before an ALJ. In most areas, you do not request a hearing unless your claim has been denied at the reconsideration level. Your local SSA office or your representative will know which type of appeal you should file.

If you are denied at the reconsideration level, you will have 60 days to appeal to an Administrative Law Judge for a hearing. Over half of the claimants who request a hearing before an ALJ will receive favorable decisions awarding benefits. At the hearing the ALJ will ask you about your child's condition and how it affects your child's ability to work and perform activities of daily living. The ALJ will ask what your child can do during the day and how the child feels after doing certain activities. Family members may also tell the ALJ about your child's condition. The ALJ may also ask a medical expert to explain Prader-Willi syndrome. You can help your claim by providing information to the ALJ before the hearing. The ALJ may also call a vocational expert who will talk about what jobs your child could perform and whether a significant number of these jobs exist. If your child has worked in the past, the ALJ will also ask the vocational expert whether your child can perform the work that he/she did before.

If the ALJ denies your claim, you have 60 days to appeal to the Appeals Council. In some parts of the country, SSA has eliminated the Appeals Council, so you would appeal directly to federal court. An Appeals Council appeal is a written form. If you disagree with the ALJ's decision, you or your representative must explain exactly what parts of the decision you think are wrong. Occasionally, the Appeals Council will ask your representative for oral argument. But this is very rare. Unfortunately, it is not uncommon to wait 1-1/2 years before the Appeals Council makes a decision. The Appeals Council will usually either send the claim back to the ALJ for another hearing or deny your claim altogether. Eighteen percent of the claims are sent back for another hearing. The Appeals Council finds that claimants are disabled without another hearing in only 2% of the appeals.

If the Appeals Council denies your claim, you can appeal to federal court. You have 60 days to file a claim in federal court. You will want representation at this level, as only an attorney can file an appeal in federal court; a non-attorney representative cannot appeal to federal court.

How Long Will the Application Process Take?

It is not uncommon for a claimant to wait 6 to 12 months for a decision on an application for disability benefits. Claims that must be appealed administratively (to an Administrative Law Judge and the Appeals Council) or to federal court will take much longer. (To provide some perspective on the program, consider that almost 3 million applications for disability benefits were filed in a recent year.) When a case is finally approved, benefits will be paid to cover the months during which the

claimant was waiting for a decision. The amount of time and effort it takes to pursue an appeal is definitely daunting. Perseverance and persistence are crucially important.

What Determines the Benefit Amount?

The amount of Social Security Disability Insurance, or Title II, benefits paid depends on the former worker's earnings throughout his/her work history, the number of years worked, his/her age, as well as the number of people in the family and its composition (including divorced spouses). For a person whose earnings, averaged over his/her working life, were \$20,000, Title II disability benefits in 2005 would be approximately \$835 monthly. A spouse and child would receive an additional \$415. For a person whose earnings averaged \$50,000, the monthly benefit amount could be approximately \$1,570. The family maximum, a cap on the monthly benefits payable on the account of a particular worker, limits the amount of Social Security benefits payable to an entire family when all benefits are based on the account of one wage earner. The effect of the family maximum, however, is that families with more children may not necessarily receive more benefits than families with fewer children, even if the Personal Income Account figures are the same.

Note that there is no family maximum for SSI benefits because each person who receives benefits does so based on his/her own impairment. It is possible, then, that a very poor family with several disabled children will receive more SSI benefits than a wage earner and dependents receiving SSDI (Title II) benefits.

The SSI benefit amount is based on the income, resources, and living arrangement of the disabled individual, and sometimes, his family. There is a federal SSI monthly benefit rate: in 2005, \$579 for an individual and \$869 for an eligible couple. Many states add a state supplement to this amount. An individual's monthly SSI benefit will be reduced by other resources and income he receives, based on SSA's formula for counting "earned" and "unearned" income. The amount of the SSI check can differ each month if the amount of income changes each month. The formula can be quite complicated. Although SSA is required to provide an explanation of how the benefits amount is calculated, it is still recommended that you ask your representative to explain the decisions in your specific case.

SSA uses a "Retrospective Monthly Accounting" method. This means that the amount of SSI benefits in any given month is determined by the income received in the second previous month. For example, the November SSI amount is based on income received in September.

In certain situations, SSA will count a portion of *another person's income* as the unearned income of an SSI recipient. This is called "deeming." It does not matter whether the other person's income is actually available to the SSI recipient. For example, if one spouse is disabled and not working, the income of the other spouse will be deemed to the disabled spouse and will affect his/her eligibility

for SSI benefits. A parent's income is deemed to a minor child and will affect the child's eligibility for SSI and benefit amount, if found eligible. This is why the disabled child in a middle class working family will not be eligible for SSI benefits. The income of a parent's spouse will also be deemed to the child, even if the spouse has not adopted the child. Deeming does not always apply if the child does not live with the parent. Special deeming rules exist if the child lives in a Medicaid-funded institution, or lives with another relative. Parent-to-child deeming ends when the child turns 18 years old. Even without deeming, this does not mean a child will be eligible for SSI. SSA looks at living arrangements also. In some states, a child who is not financially eligible for SSI may still be eligible for Medicaid. Certain types of income, such as other types of welfare benefits, are not deemed.

When determining the monthly SSI benefit amount, SSA will also consider the individual's living arrangements. If an SSI recipient lives with another person and receives food, clothing, or shelter from that person, SSA calls this "in-kind support and maintenance" and includes the value as income. If the SSI recipient can show that he has been *loaned* the support and maintenance and has an obligation to repay it, it will not affect the amount of assistance.

If an SSI recipient is living in another person's house and receiving both food and shelter from that person, SSA will apply what is called a "one-third reduction rule." However, if the recipient is paying a pro rata share of household expenses, or buying his own food, then he is not considered to be living in the household of another and is not subject to the one-third reduction rule. Instead, he is subject to the "presumed value rule."

The main difference between the one-third reduction rule and the presumed value rule is that, under the one-third reduction rule, SSA will reduce the federal monthly SSI benefit by one third (\$193, based on the 2005 monthly benefit of \$579). The actual value of the support does not matter. Under the presumed value rule, SSA starts with a presumption that the value of the in-kind support is worth one third of the federal benefit rate. However, if you can show that the actual value is less than one third of the federal benefit rate, SSA will use the lower number and will reduce the SSI check by the lower amount.

In addition, SSA will deduct other income, as well as disregard certain amounts of earnings before determining the monthly benefit amount.

Once Approved, Can I Work and Continue to Receive Social Security or SSI Benefits?

SSA has many work incentive programs, which allow recipients to work for a limited amount of time, or under special circumstances, without losing their benefits. Most people who receive Social Security Disability benefits can earn up to \$590 per month (in 2005) for 9 months

while receiving their benefits. This is called a Trial Work Period. After the 9 months are completed, a beneficiary can work during the following 3 years. Benefits will not be paid for any month in which you earn over \$590, but you will receive benefits for any month you do not work. If you are still working at the end of the 3-year period, benefits may be terminated.

Another work incentive available is called Impairment Related Work Expenses (IRWE). If you have certain expenses because of your disability that permit you to work, you can deduct the cost of these expenses from your income. For example, if your seizures prevent you from driving, and there is no public transportation available, or if you are unable to take public transportation, the cost of a taxi to and from work can be deducted from your earnings. SSA will deduct the difference between the cost of the taxi and the cost of the bus that you cannot use. Deducted expenses will not be counted as earnings. This can be used to bring your earnings below the monthly Substantial Gainful Activity level (\$830 for 2005). The amount of money considered an IRWE will not be counted as income and will not cause a reduction in your SSI check.

You can also create a PASS Plan. This is a Plan for Achieving Self Support. A PASS plan is a written plan that must be approved by SSA in advance. It permits you to set aside some money earned towards an educational or occupational goal. The money set aside will not be counted as income for Title II or SSI purposes. This can be used to bring your earnings below the monthly substantial gainful activity level, and SSA will then find that you are not “working.” The amount of money set aside under a PASS plan will not be counted as income and will not cause a reduction in your SSI check.

SSA has recently started a “Ticket to Work Program,” which also permits recipients of disability benefits do to some work while receiving benefits and continued Medicare coverage. People can use their Ticket to get free vocational rehabilitation, job training, and other employment support services. SSA’s Web page has information on the Ticket to Work Program and other work incentives that are available. Look at www.socialsecurity.gov or call SSA at 1-800-772-1213.

It is not advisable to return to work before you have received a favorable decision on disability applications. Recipients who are considering trying to work should look at SSA’s Web page, and contact SSA at 1-800-772-1213 or an attorney who is familiar with Social Security programs for specific guidance.

How Can I Get Help or Additional Information?

Additional information can be obtained from SSA by calling 1-800-772-1213 or looking at their Web page at www.socialsecurity.gov. Most people apply for benefits on their own but often want assistance in pursuing an appeal. If you need legal representation to assist you in obtaining Social Security disability or SSI benefits, contact your local

legal services program or your local bar association referral office. Or you can get a referral to a private attorney in your area from the National Organization of Social Security Claimants' Representatives by calling 1-800-431-2804.

Appendix E

The International Prader-Willi Syndrome Organization

The International Prader-Willi Syndrome Organization (IPWSO) is a global organization of 60 member and associate countries committed to enhancing the quality of life for people with Prader-Willi syndrome and their families, giving our children the best possible opportunities for living their lives to the fullest. This international community of parents, friends, and professionals forms a dedicated network. It connects families and professionals, provides emotional and educational support, spreads general awareness, educates, and encourages scientific research. Regional and international conferences are especially helpful in giving families the occasion to come together for educational workshops and lectures, while also providing a forum for scientists.

Most significantly, IPWSO helps families—even in the most remote corners of the world—understand that they are not alone in dealing with the challenges of this complex syndrome. We provide a window to support and services that already exist within a member country. Where no support exists, we help fledgling associations with their development.

Since education promotes the possibility for early diagnosis and early interventions in medical and behavioral management, spreading awareness is a major goal of IPWSO. Our educational packets (“General Awareness,” “Crisis,” and “Medical Awareness”) cover a wide range of essential topics and are distributed throughout the world in many languages.

IPWSO is an organization without borders—open to people of all origins and cultures. Families, researchers, clinical physicians, and other professionals from all over the world are a part of our network and our family. Please check our Web site (www.ipwso.org) to see if your country has a national association. If it doesn't, contact us and we will assist you in forming an association, and we will connect you to other resources in your region, as well as throughout the world. We invite you to join our global family. With nations working together and sharing our resources and goals, IPWSO provides a beacon of hope for a better life for children with PWS and their families. With love and determination, all people with PWS can have a brighter future!

Please feel free to contact us for information or assistance:

Pam Eisen
IPWSO President
E-mail: pam@ipwso.org

Giorgio Fornasier
IPWSO Director of Program Development
E-mail: g.fornas@libero.it



Main office:
IPWSO
c/o Baschirotto Institute of Rare Diseases (B.I.R.D.)
Via Bartolomeo Bizio, 1—36023 Costozza (VI)—Italy
Tel/Fax: +39 0444 555557
E-mail: ipwso@birdfoundation.org
Web site: www.ipwso.org

IPWSO Members

The following are member countries and contacts as of March 2005:

ARGENTINA

Web site: www.praderwilliARG.com.ar
Professional delegate: Dr. Hector Waisburg, Larrea 1474, (1117) Buenos Aires, Argentina
Tel: +54 14806 4187
Fax: +54 14807 4773
E-mail: waisburg@fibertel.com.ar
Parent delegate: Elli Korth, Forly 680 Loma Verde 1625 Escobar, Pcia. De Bs. As. Argentina
Tel/Fax: +54 3488 493499, +54 155 376 9541
E-mail: ellik@datamarkets.com.ar

AUSTRALIA

Web site: www.pws.org.au
Professional delegate: Dr. Ellie Smith, 23-25 Neil St., Bundeena NSW 2230 Australia
Tel: +61 2 9527 9795 (home), + 61 2 9845 3237 (work)
E-mail: ellies@nch.edu.au
Parent delegate: Ms. Vanessa Crowe, 1 Barron Street, DEAKIN ACT 2600 Australia
Tel: +61 2 6282 1167
E-mail: one.barron@bigpond.com

AUSTRIA

Web site: www.prader-willi-syndrom.at
Professional delegate: Dr. Barbara Utermann, Humangenetische Beratungsstelle, Schöpfstraße 41, A-6020 Innsbruck, Austria

Tel: +43/512/507-3451

Fax: +43/512/507-2861

E-mail: Barbara.Utermann@uibk.ac.at

Parent delegate: Dr. Verena Wanker-Gutmann, Schloß Frohnburg, Hellbrunner Allee 53, A-5020 Salzburg, Austria

Tel: +43 662 624 142

Fax: +43 662 620 826-75

E-mail: frohnburg@salzburg.co.at

E-mail: frohnburg@moz.ac.at

BELGIUM

Professional delegate: Dr. Annick Vogels, C.M.E., KU Leuven, Herestraat 49 B-3000, Belgium

Tel: +32 1634 5903

E-mail: Annick.Vogels@uz.kuleuven.ac.be

Parent delegate: Wilfried De Ley, Prader-Willi Vereniging vzw Belgium, Boechoutsesteenweg 54, B-2540 Hove, Belgium

Tel: +32 3455 6691

Fax: +32 3221 0723

E-mail: wilfried.deley@pandora.be

BOLIVIA

Professional delegate: Carlos A. De Villegas Córdova, M.D., Pediatra Intensivista Av. Pablo Sanchez N° 6763 (Irpavi) Bolivia

Tel: +591-2-2430123, +591-2-2433933, +591-2-71521099 (cell)

E-mail: cadevico@hotmail.com

Parent delegate: Luz Elizabeth Tejada Velez, Casilla N.6861, La Paz, Bolivia

E-mail: eliteve19972@hotmail.com

BRAZIL

Web site: http://geocities.yahoo.com.br/prader_willi_br/

Parent delegate: Gelci Galera, Rua Dom Wilson Laus Schmidt, 303 Córrego Grande, Florianópolis SC CEP 88037-440 Brasil

Tel: +55 48 2330753

E-mail: gelci@estadao.com.br

E-mail: assocnacspw@yahoo.com.br

CANADA

Web site: www.pwsacanada.com

Professional delegate: Dr. Glenn Berall, BSc, M.D., FRCP(C), 4001 Leslie Street, Toronto, ON M2K 1E1 Canada

Tel: +1-416-756-6222

Fax: +1-416-756-6853

E-mail: gberall@nygh.on.ca

Parent delegate: Diane Rogers, P.O. Box 786 Kensington, PEI COB IM0 Canada

Tel: +1-902-836-4452

E-mail: gdrogers@pei.sympatico.ca

CHILE

Web site: www.prader-willi.cl

Professional delegate: Dra. Fanny Cortes, Tabancura 1515 Of 210, Vitacura, Santiago, Chile

Tel: +56 2 678 1478

Fax: +56 2 215 2582

E-mail: fcortes@prader-willi.cl

Parent delegate: Carlos Molinet, 1a Transversal 10252, Dpto 41, El Bosque, Santiago, Chile

Tel: +56 2 559 2343, +56 9 276 9068

E-mail: cmolinet@prader-willi.cl

E-mail: info@prader-willi.cl

CHINA

Professional delegate: Jinghua Chai, M.D., M.Sc., Research Associate, Department of Psychiatry, University of Pennsylvania, Clinical Research Building, Room 530, 415 Curie Blvd. Philadelphia, Pennsylvania 19104-6140, U.S.A.

Tel: +1-215-898-0265

Fax: +1-215-898-0273

E-mail: jinghuachai@yahoo.com

COLOMBIA

Professional delegate: Dr. Alejandro Velásquez, endocrinólogo pedia-
tra, Calle 2 sur # 46-55 Fase 1. Clinica Las Vegas, Consultorio 223,
Medellin, Colombia

Tel: +2683763, +3108398091 (cell)

E-mail: alejandrov@doctor.com

Parent delegate: Jorge Restrepo, Apartado Aéreo 11667, Medellin,
Colombia

E-mail: jerestrepo@epm.net.co

CROATIA

Professional delegate: Prim. Dr. Jasenka Ille, KBC Zagreb, Rebro,
Kispaticева 12, 10000 Zagreb, Croatia

Tel: +385 1 2388 331

Parent delegate: Ivka Cop and Davor Matic, Bukovacka 158, 10000
Zagreb, Croatia

Tel: +385 9 1 5190 661

E-mail: ivkacop@net.hr

CUBA

Parent delegate: Ilieva Vazquez Bello, 9525 SW 24 St. Apt. D-102,
Miami, FL 33165, U.S.A.

Tel: +1-305-207-5739

E-mail: ilimigue@hotmail.com

Address in Cuba: F.lia Vazquez, Calle 4ta #10810, E/7MA Y 9NA Casino
Deportivo Ciudad Habana, Cuba

Tel: +41-89-06, +880-27-20 (cell)

DENMARK

Web site: www.prader-willi.dk

Professional delegate: Susanne Blichfeldt, M.D., The Danish PWS Association, Kildehusvej 12, DK-4000 Roskilde, Denmark

Tel: +45 4637 3204, +45 4637 3203

E-mail: s.blichfeldt@dadlnet.dk

Parent delegate: Børge Troelsen, Agervej 23, DK-8320 Mårslet, Denmark

Tel: +45 8629 2141

Fax: +45 8629 2191

E-mail: b.troelsen@email.dk

DOMINICAN REPUBLIC

Professional delegate: Dra. Cristian López Díaz, Neurólogo-Neuropediatra Grupo Médico Naco, C/ Fantino Falco No. 12, Suite No. 5 2do piso, Esanche Naco, Santo Domingo Rep. Dom.

Tel: +809-685-5544, +809-759-8800 (cell)

E-mail: crislopezdiaz@hotmail.com

Parent delegate: Julia Bonnelly, Continental Express, SA 5171, P.O. Box 25296, Miami, Florida 33102, U.S.A.

Tel: +1-809-582-3417

E-mail: jbonnelly@navierasbr.com

ECUADOR

Parent delegate: Jorge Oswaldo Zúñiga Gallegos, Urbanización Carlos Montufar, Calle Isla Puná No. 8, San Rafael, Casilla Postal No. 17-23-159, Quito Ecuador

Tel: +593 2 2860-985, +593 2 2865-047

E-mail: jzuniga@espe.edu.ec

Other contact: Armando Castellanos, Reina Victoria 17-37 y La Niña, Quito-Ecuador

Tel: +593 2 2683-647

E mail: iznachi@yahoo.com.mx

EGYPT

Professional delegate: Osama K. Zaki, M.D., Cytogenetics Unit. Dept Of Pediatrics, Ain Shams University, 8, Kamal Raslan St. Heliopolis, Cairo 11771 Egypt

Tel: +20 2 2717445

Fax: +20 2 2731933

E-mail: ozaki@medical-genetics.net

Parent delegate: Omnia Mourad, One Mohamed El Nadi Street, Makram Ebeid, 6th Zone, Nasr City, Egypt

E-mail: omneya@medical-genetics.com

EL SALVADOR

Professional delegate: Dr. Billy Fuentes, 3^a Calle Poniente y 79 Av. Norte, Local N° 110 Condominio Las Alquerias, Colonia Escalon, San Salvador, El Salvador, Centro America

Tel: +503-264-6990 (work), +503-274-4936 (home)

E-mail: bimifu@hotmail.com

Parent delegate: Mario A. Méndez, Colonia Pórtico San Antonio #13—A Calle San Antonio Abad., San Salvador, El Salvador, Centro America

Tel: +503-284-4032

E-mail: mariomenra@hotmail.com

FINLAND

Web site: www.prader-willi.dk

Professional delegate: Dr. Ilkka Sipilä, M.D., HUCH Hospital for Children and Adolescents, (Stenbäckinkatu 11, 00290 Helsinki), P.O. Box 281, FIN-00029 HYKS, Finland

Tel: +358 50 427 2898

Fax: +358 94 717 5888

E-mail: ilkka.sipila@hus.fi

Parent delegate: Tiina Silvast, Teekkarinkatu 17 B 15, 33720 Tampere, Finland

Tel: +358 40 084 7576

Fax: +358 3 213 3301

E-mail: tiina.s@pp1.inet.fi

FRANCE

Web site: <http://perso.wanadoo.fr/pwillifr/>

Professional delegate: Prof. Raphael Rappaport, Hôpital Necker, Département de Pédiatrie, Unité d'endocrinologie et croissance, 149 Rue de Sèvres, F-75743 Paris Cedex 15, France

Tel: +33 144 494 801

Fax: +33 144 494 800

E-mail: raphael.rappaport@nck.ap-hop-paris.fr

Parent delegate: Jean-Yves Belliard, 10 Rue Charles Clément, F-02500 Mondrepuis, France

Tel/Fax: +33 323 987 904

E-mail: jean-yves.BELLIARD@wanadoo.fr

GERMANY

Web site: www.prader-willi.de/

Professional delegate: Dr. Gillessen-Kaesbach, Humangenetisches Institut, Hufelandstr. 55D-45112 Essen, Germany

Tel: +49 201 723 4563

Fax: +49 201 723 5900

E-mail: g.gillessen@uni-essen.de

Parent delegate: Monika Fuhrmann, Weiherstr. 23, D-68259 Mannheim, Germany

Tel: +49 621 799 2193

E-mail: monikafuhrmann@web.de

GREECE

Professional delegate: As. Professor Dr. Christina Kanaka-Gantenbein, MD, Pediatric Endocrinology and Diabetes, 1st Department of Paediatrics, University of Athens, 52 Kifissias Ave., 115 26 Athens, Greece

Tel: +30 1 777 9909

E-mail: ganten@hol.gr

Parent delegate: Maria Papaiordanou, Ploutonos 1 & Themistokleous St., 17455 Kalamaki—Alimos, Athens, Greece

Tel: +30 210 981 8179

Fax: +30 210 413 4648

E-mail: harmar@hol.gr

GUATEMALA

Professional delegate: Licda. Q.B. Mayra Urizar, Laboratorio Bioanalisis 18 Av. 4-50 zona 3, Quetzaltenango, Guatemala, C.A.

Tel: +502 77674597, +502 54070806 (cell)

E-mail: mayraurizar@intelnet.net.gt

E-mail: mayraurizar@cabledx.tv

Parent delegate: Luis Barrios Izaguirre, 6a Calle "C" 4a-25 zona 9, Los Cerezos I Quetzaltenango, Guatemala, Centro America

Tel: +502 7677202, +502 54033260 (cell)

E-mail: luisbarrios@cabledx.tv

HONDURAS

Professional delegate: Dr. Jose Armando Berlioz Pastor, Colonia Altos de Miramontes, Diagonal Aguan # 2751 Tegucigalpa, M.D.C. Honduras, C.A.

Tel: +504-232-4429 (home), +504-221-1939 (office), +504-992-4569 (cell)

E-mail: aberlioz@quik.com

ICELAND

Professional delegate: Stefan Hreidarsson, M.D., Medical Director, State Diagnostic and Counseling Centre, Digranesuegur 5, 200 Kopavogur, Iceland

Tel: +354 510 8400

E-mail: STEFAN@Greining.is

INDIA

Professional delegate: Dr. Arun Kumar, Asst. Professor of Human Genetics, Indian Institute of Science, Bangalore 560 012, India

Tel: +91 80 2293 2998 (office), +91 80 2346 5523 (home)

Fax: +91 80 2360 0999

E-mail: Kumarkarun@mrdg.iisc.ernet.in

Parent delegate: Shikha Metharamani, 16\1, Loudon Street, 3D Loudon Park, Kolkata-700 017 W. Bengal, India

Tel: +91 33 2247 2765, +91 98 3100 8191 (cell)

E-mail: shikha_harlalka@hotmail.com

ISRAEL

Web site: www.pwsil.org.il

Professional delegate: Varda Gross-Tsur, M.D., P.O. Box 2210, Mevasseret Zion 90805, Israel

Tel: +972 2 5341193

Fax: +972 2 6422481

E-mail: gros_fam@netvision.net.il

Parent delegate: Urith Boger, P.O. Box 1332, 31 Aya St., Ramat Hasharon 47226, Israel

Tel: +972 3 5409882

Fax: +972 3540 5271

E-mail: koshi1@netvision.net.il

ITALY

Web site: <http://digilander.libero.it/praderwilli/main.htm>

Professional delegate: Dr. Laura Bosio, c/o Pediatric Dept, Endocrine Unit, St.Raphael Hospital, Via Olgettina 60, 20132 Milano, Italy

Tel: +39 0226 432 625

Fax: +39 0226 432 626

E-mail: bosio.laura@hsr.it

Parent delegate: Giuseppe Quaglia, Via Cascina Maffeis, 72 24052 Azzano S. Paolo (BG), Italy

Tel: +39 035 530646

Fax: +39 035 531040

E-mail: beppe@quaglia.it

JAPAN

Professional delegate: Dr. Tomoko Hasegawa, M.D., Genetic Support & Consultation Office (GeSCO), 1-3-5-102 Kami-ashi-arai, 420-0841 Shizuoka, Japan

Tel: +81 5 4248 0457

Fax: +81 3 3944 6460

E-mail: hasemoko@aol.com

Parent delegate: Kazue Matsumoto, Sanjo-cho 33-11, Asiya-city, Hyogo-prefecture, Japan

Tel: + 81 7 9738 3087

E-mail: takumama@kcc.zaq.ne.jp

KOREA

Parent delegate: Jang Eunju, R# 303, 2FL, 165-13, Seokchon-dong, Songpa-gu, Seoul, Korea, 138-844

Tel : +016 733 4497 (cell)

E-mail: jenovia2000@yahoo.co.kr

MALAYSIA

Professional delegate: Dr. Yew Sing Choy, Pediatric Institute Kuala Lumpur Hospital, Jalan Pahang, 50586 Kuala Lumpur, Malaysia

Tel: +60 3 2615 5555, ext. 6889

Fax: +60 3 2694 8187

E-mail: choyo@tm.net.my

Parent delegate: Azmi Baba, Royal Malaysia Police Air Unit, Old Airport Road, 50460 Kuala Lumpur, Malaysia

Tel: +60 3 2282 5868

Fax: +60 3 2282 4535

E-mail: abhb57@hotmail.com

MEXICO

Web site: <http://praderwilli.es.mn>

Professional delegate: Carlos Alberto Meza Miranda, Av de los Balsos No. 68 Fracc. Villas del Tey, Mexicali Baja California, Mexico c.p. 21380

Tel: +52 686 5 58 37 01

E-mail: cmezamiranda@yahoo.com.mx

Parent delegate: Diana Cota (same address as Carlos)

E-mail: dianaoliviacota@hotmail.com

MOLDAVIA

Professional delegate: Dr. Victoria Sacara, Apt. 144, 21 Dacha str., Kishinev, Moldova MD 2038

Tel: +373 719670

E-mail: vsacara@mednet.md

Parent delegate: Baranova Tatiana, Apt.12, 23 Renashterey str., Kishinev, Moldova 2005

Tel. +226386

E-mail: tatiaser@araxinfo.com

MOROCCO

Parent delegate: Mme Fatima Mandili, 6 bis Rd doukkala rue Soulaïmane Azzmi Appt. 4 Qu Hopitaux 20000 Casa, Maroc

E-mail: fate\lkorno@hotmail.com

THE NETHERLANDS

Web site: www.praderwillisyndroom.nl

Professional delegate: Prof. Dr. Leopold M.G. Curfs, University Maastricht/Academic Hospital Maastricht, Department Clinical Genetics, P.O. Box 1475, 6201 BL Maastricht, The Netherlands

Tel: +31 43 3877850, +31 43 38775899

E-mail: curfs@msm.nl

Parent delegates: Gerard Meijwaard, Louis Pasteurpad 28, 6216 EV Maastricht, The Netherlands

Tel: +043 3432371

E-mail: Gerard@praderwillisyndroom.nl

Tamara Stranders, Prader-Willi/Angelman-Vereniging, Postbus 85276, 3508 AG Utrecht

Tel: +31 30 2363763

E-mail: t.stranders@fvo.nl

NETHERLANDS ANTILLES

Parent delegate: Marisol Punín, Wolfstraat #4, Noord Aruba, Antillas Holandesas

Tel: +297 9 931869, +297 5 837175 (work)

E-mail: solibeca@hotmail.com

NEW ZEALAND

Web site: www.pwsa-nz.co.nz

Professional delegate: Dr. Esko Wiltshire, Paediatric Endocrinologist, Wellington Hospital, Wellington, New Zealand

E-mail: esko@wcmeds.ac.nz

Parent delegate: Linda Thornton, P.O. Box 143, Masterton, New Zealand

Tel: +64 6306 8424

Fax: +64 6306 8425

E-mail: pwsanz@wise.net.nz

NIGERIA

Parent delegate: Charles Ch. Mayberry, Erdkampsweg 6, 22335 Hamburg, Germany

Tel: +49 40 5204217

Fax: +49 40 5203317

E-mail: Maybec3@aol.com

NORWAY

Web site: www.praderwilli.no

Professional delegate: Christian Aashamar M.Ed., Frambu, Sandbakkveien 18, N-1404 Siggerud, Norway

Tel: +47 64 85 60 80

Fax: +47 64 85 60 99

E-mail: caa@frambu.no

Parent delegate: Ragnhild Øverland Arnesen, Kollbulia 22, N-5124 Morvik, Norway

Tel: +47 55 18 48 42, +47 48 09 67 09 (cell)

E-mail: ragnhoa@online.no

PAKISTAN

Professional delegate: Dr. Jamal Raza, Associate Professor, National Institute of Child Health, Rafiquee Shaheed Road, Karachi 75510, Karachi, Pakistan

Tel: +9201261 4, ext. 223, +0333 2184376 (cell)

E-mail: jamalraza@yahoo.com

Parent delegate: Ghazala Nomani, 26 Cedar St., Bergenfield, New Jersey 07621, U.S.A.

Tel: +1-201-244-9026

E-mail: gnpwspak@aol.com

PANAMA

Parent delegate: Kathia Díaz Arias, San Miguelito Samaria, Sector 4b, casa 161, Panama

Tel: +507-273-9591

E-mail: angeldavid134@LatinMail.com

PARAGUAY

Professional delegate: Dra. Maria Beatriz N.P. de Herreros, Domingo Portillo 1508 C/ Prof. Fernandez Asuncion, Paraguay

Tel: +595 21 298564

Fax: +595 21 223738

E-mail: mara@cmm.com.py

Parent delegate: Ing. Ubaldo Gonzalez Franco, Villa del Agronomo,
Lote Guazù, San Lorenzo, Paraguay
Tel: +595 981 932064
Fax: +595 981 584546
E-mail: danny_winner5@hotmail.com

PERU

Professional delegate: Dr. Alberto Teruya Gibu, Av. Iquitos 293 La
Victoria, Lima, Peru

Tel: +51 1 4248007
E-mail: aatg2002@yahoo.com

Parent delegate: Rosalva Espino Moscoso, José Pardo 159, Urb. Astete,
San Miguel, Lima, Peru

Tel: +51 1 4206367
E-mail: rosalves@yahoo.com

PHILIPPINES

Parent delegate: Regina Infante, Blk.3 Lot 10 Phase 5 Adalia Street,
Elvinda Village, San Pedro, Laguna, Philippines 4023

Tel: +63 917 5011915
E-mail: regina_infante@hotmail.com

Other parent contact: Vienne Go Ang, #45 11th Street, New Manila,
Quezon City, Philippines

E-mail: vienne@i-manila.com.ph

POLAND

Professional delegate: Ewa Obersztyn, M.D., Ph.D., Department of
Medical Genetics, National Institute of Mother and Child, 01-211
Warsaw, ul. Kasprzaka 17a, Poland

Tel: +48 22 32 77 490
Fax: +48 22 32 77 152
E-mail: eobersztyn@imid.med.pl

Parent delegate: Maria Libura, 02-132 Warsaw, ul. Baleya 4/11
Poland

Tel: +48 22 65 98 778
E-mail: marialibura@op.pl

PORTUGAL

Professional delegate: Prof. Luis Nunes, Conselho de Administração,
Hospital D. Estefania, Rua Jacinta Marto, 1169-045 Lisboa, Portugal

Tel: +351 914 907 550
E-mail: luis.nunes@sapo.pt

Parent delegate: Paula Costa, c/o "Rarissimas," Associação Nacional
de Deficiências Mentais e Raras, Rua dos Bons Amigos, Lote 348 Casal
do Bispo, 1685-843 Farnelos, Portugal

Tel: +351 217 956 205
Fax: +351 217 969 777
Web site: www.rarissimas.org
E-mail: cdlsPaulacosta@yahoo.com

PUERTO RICO

Professional delegate: Alberto Santiago Cornier, M.D., Ph.D., Ponce School of Medicine, Genetic Division, P.O. Box 7004, Ponce PR 00732, Puerto Rico

Tel: +1-787-840-2575, ext. 2218/2213/2156

Fax: +1-787-840-5698

Parent delegate: Elsa Alago, Calle El Cerezal F-5, Jardines de Miramar, Isabela PR 00662 Puerto Rico

Tel: +1-787-830-0439 (home), +1-787-834-8000, ext. 2214 (work), +1-787-645-5483 (cell)

E-mail: ealago@tld.net

ROMANIA

Professional delegate: Szekely Aurelia, Endocrinologist—doctor in medicine, Zalau, str. Oborului, nr.10, Romania

Tel: +40 260 662672, +40 074 2070123 (cell)

E-mail: aurelia_szekely@k.ro.

Parent delegate: Dorica Dan, Str. Simion Barnutiu, nr.97, bl. SB 88, apt.14, Loc. Zalau, Judet Salaj, Cod 4700 Romania

Tel: +40 60 616585, +40 726 248707

E-mail: doricad@yahoo.com

SAUDI ARABIA

Professional delegate: Dr. Mazin S. Fakeeh, M.D., FRCP, Dr. Soliman Fakeeh Hospital, Palastine St. Jeddah, 21461. P.O. Box 2537, Saudi Arabia

Tel: +9662 6655000

E-mail: mazin@drfakeehhospital.com

SINGAPORE

Professional delegate: Denise Li-Meng Goh, The Children's Medical Institute, National University Hospital, Assistant Professor, Dept. of Pediatrics, National University of Singapore, 5 Lower Kent Ridge Road, S 119074, Singapore

Tel: +65 6772 4420

Fax: +65 6779 7486

E-mail: paegohlm@nus.edu.sg

Parent delegate: Eric and Lina Khoo, Blk 721 Pasir Ris St 72 #07-115 S510721 Singapore

Tel: +65 9818 0582

E-mail: linakhoo@gmail.com

SLOVENIA

Professional delegate: Prof. Ciril Kržišnik, University Medical Center Ljubljana University Children's Hospital, Vrazov trg 1, 1000 Ljubljana, Slovenia

Tel: +386 61 320 887

Fax: +386 61 310 246

E-mail: ciril.krzisnik@mf.uni-lj.si

Parent delegate: Mirjana Zokalj, Mirje 25, 1000 Ljubljana, Slovenia
Tel: +386 61 126 23 10
Fax: +386 61 125 24 86
E-mail: vojteh.zokalj@siol.net

SOUTH AFRICA

Web site: www.praderwilli.org.za

Professional delegate: Dr. Engela M. Honey, Department of Human Genetics, University of Pretoria, P.O. Box 2034, 0001 Pretoria, South Africa

Tel: +27 82 5795315

E-mail: ehoney@medic.up.ac.za

Parent delegate: Rika du Plooy, 267 Middelberg Street, Muckleneuk, 0002 Pretoria, South Africa

Tel: +27 12 3440241

E-mail: rikadup@mweb.co.za

SPAIN

Web site: www.prader-willi-esp.com/

Professional delegate: Dr. Fernando Mulas, Jefe de Neuropediatria, Hospital Universitario "LA FE", Avda. Campanar, 21, 46020 Valencia, Spain

Tel: +34 96 386 2700, ext. 50481

Fax: +34 96 362 3194

E-mail: fmulasd@meditex.es

Parent delegate: Maria Helena Escalante, Ramón Lujan, 41-3A, 28026 Madrid, Spain

Tel: +34 91 500 3761, +34 61 925 5813 (cell)

E-mail: osandre@inicia.es

SWEDEN

Professional delegate: Professor Martin Ritzén, Pediatric Endocrinology, Karolinska Hospital, S-171 76 Stockholm, Sweden

Tel: +46 8 5177 2465

Fax: +46 8 5177 5128

E-mail: Martin.Ritzen@kbh.ki.se

Parent delegate: Jean Phillips-Martinsson, Farthings 44 Warwick Park, Tunbridge Wells, Kent TN2 5EF, United Kingdom

Tel/Fax: +44 1892 549492

E-mail: jeanpws@compuserve.com

SWITZERLAND

Web site: www.Prader-Willi.ch

Professional delegate: PD Dr. med. Urs Eiholzer, Foundation Growth Puberty Adolescence, Möhrlistr. 69, CH-8006 Zürich, Switzerland

Tel: +41 1364 3700

Fax: +41 1364 3701

E-mail: mail@childgrowth.org

Parent delegate: Doris Bächli, Im Vogelsang, CH 9477 Trübbach, Switzerland
 Tel: +41 81 783 2601
 E-mail: Mail@prader-willi.ch

TAIWAN

Web site: <http://home.pchome.com.tw/health/twpws>
Professional delegate: Dr. Shuan-Pei Lin, Division of Genetics, Dept. of Pediatrics, McKay Memorial Hospital, 92 Chung-San N. Road, Sec. 2, Taipei, Taiwan
 Tel: +886 2 2543 3585/3089
 Fax: +886 2 2543 3642
 E-mail: zsplin@ms2.mmh.org.tw
Parent delegate: Welly Chan, 7th Fl. We Sheng Building, No. 125 Nan-King East Road Sec. 2, Taipei, Taiwan
 Tel: +886 2 2508 6626
 E-mail: wellyvivian@yahoo.com

THAILAND

Professional delegate: Duangrurdee Wattanasirichaigoon, M.D., 270 Rama VI Rd., Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Department of Pediatrics, Division of Medical Genetics, Bangkok 10400 Thailand
 Tel: +66 2201 1488
 Fax: +66 2201 1850
 E-mail: radwc@mahidol.ac.th

UNITED KINGDOM

(England, Scotland, Wales, Ireland)

Web site: www.pwsa.co.uk
Professional delegate: Prof. A.J. Holland, 2nd Floor, Douglas House, 18b Trumpington Road, Cambridge CB2 2AH, U.K.
 Tel: +44 1223 746112
 Fax: +44 1223 746122
 E-mail: ajh1008@cam.ac.uk
Parent delegate: Jackie Waters, 125a London Road, Derby DE1 2QQ England
 Tel: +44 1332 365676
 Fax: +44 1332 365401
 E-mail: JWaters@pwsa-uk.demon.co.uk

UNITED STATES OF AMERICA

Web site: www.pwsausa.org
Professional delegate: Suzanne B. Cassidy, M.D., Clinical Professor, Department of Pediatrics, Division of Medical Genetics, UCSF, 533 Parnassus Avenue, Rm U100A, San Francisco, CA 94143-0706, U.S.A.
 Tel: +1-415 476-2757
 Fax: +1-415 476-9976
 E-mail: scassidy@uci.edu

Parent delegate: Janalee Heinemann, Executive Director of PWSA (USA),
5700 Midnight Pass Road, Suite 6, Sarasota, Florida 34242, U.S.A.
Tel: +1-800-926-4797, +1-941-312-0400
E-mail: execdir@pwsausa.org

URUGUAY

Professional delegate: Dra. Maria Cristina Suarez, Torre Artigas Ap
507, Maldonado (20000), Uruguay
Tel: +598 42 232946
E-mail: aldebarr@adinet.com.uy

Parent delegate: Fanny Acosta, Calle Ventura Alegre 818, 20000
Maldonado, Uruguay
Tel: +598 42 225531
E-mail: paulag@adinet.com.uy

VENEZUELA

Professional delegate: Imperia Brajkovich, Hospital de Clinicas
Caracas, Avenida Los Proceres-San Bernardino, Caracas, Venezuela
Tel: +58 212 978 0462
E-mail: vamilo@cantv.net

Parent delegate: Alicia M. Turio de Borga, Calle Icabaru con Calle
Chulavista, Residencias Sierra Nevada, Apto 13-B, Colinas de Bello
Monte, 1060 Caracas, Venezuela
Tel: +58 212 754 0353 (home), +58 212 951 0542/0538 (office)
E-mail: familiaborga@cantv.net

Appendix F

The Prader-Willi Syndrome Association (USA)

PWSA (USA)
5700 Midnight Pass Road, Suite 6
Sarasota, Florida 34242 USA
Telephone: 941-312-0400
Toll-free telephone (U.S. and Canada): 800-926-4797
Fax: 941-312-0142
E-mail: pwsausa@pwsausa.org
Web site: www.pwsausa.org



The Prader-Willi Syndrome Association (USA)—PWSA (USA)—is the only national membership organization for children and adults with Prader-Willi syndrome and their families in the United States. PWSA (USA) has been serving children and adults with the syndrome for nearly 30 years. At the time of this writing, the Association also has 33 state and regional chapters, which carry out a range of activities to serve local families and support the mission of the national organization. PWSA (USA) became incorporated in 1977 and was approved for tax-exempt 501(c)3 status as a charitable organization by the U.S. Internal Revenue Service. By 1988, the Association had become a multifaceted international organization, and it currently serves members from 32 other nations in addition to its U.S. members.

Educational Materials—No other resource in the world provides as extensive a range of educational and syndrome management publications as those provided by PWSA (USA). Thanks to thousands of hours of donated time and skills by professionals and parents (often parents who are professionals in a related field), PWSA (USA) provides 35 educational books and/or booklets, 14 brochures, and several videos that cover various topics on medical, emotional, and behavioral management. PWSA (USA) mails, at no cost to the recipients, thousands of awareness and educational packets yearly. Association members are regularly kept up to date through PWSA's bimonthly newsletter, *The Gathered View*, and through articles posted on the PWSA (USA) Web site.

National Conference—The annual national conferences sponsored by PWSA and hosted by the state chapters are the largest in the world (averaging over 1,000 attendees) specifically for education and support for those dealing with Prader-Willi syndrome. This conference is actually several conferences occurring simultaneously—for scientists and other medical professionals, for adult service providers and teachers, for parents and relatives, for those with PWS, and for siblings.

Research—PWSA (USA) has two active medical advisory boards. Its Scientific and Clinical Advisory Boards are comprised of volunteer professionals from around the nation who are researchers and/or medical specialists who treat individuals with the syndrome. PWSA (USA) grants small start-up funding for research projects. The Association also impacts research in many other ways such as advocating for government and private funding of research projects, networking researchers, and through its Clearinghouse Project for research data on PWS.

Medical Intervention Support—Hospitals, physicians, and parents from all over the world consult with PWSA (USA) for medical emergencies and questions daily. Through phone, fax, and e-mail, PWSA (USA) consults with its medical boards and responds to all through a Triage Support System.

Crisis Intervention and Prevention Program—A significant role of the national office is to assist with crisis situations. This is done through the support of a qualified crisis counselor via phone and e-mail consults and networking with specialists on the syndrome from around the nation, PWSA publications, and individualized crisis packets, each containing very specialized letters to address the crisis at hand (see Chapter 19). Our executive director, the crisis counselor, and several of the medical board members consult with attorneys and teleconference with schools and courts.

New Parent Mentoring Program—Coordinated and supported by parent volunteers, this program has the greatest impact on early intervention and prevention, as experienced parents work one-on-one with newly diagnosed families. Early diagnosis, education, and awareness are the keys to prevention of life-threatening obesity and years of isolation and emotional trauma to the family of the child with Prader-Willi syndrome. Early intervention can also save thousands of dollars in medical expense and greatly reduce emotional stress on families.

Bereavement Follow-up Program—This program consists of four separate mailings to bereaved families within the first year after the death of their child. This support program also includes a one-time packet to PWS parents who lose a spouse or another child. Bereavement phone support is also offered.

Technology and International Support—Traffic to PWSA's Web site averages over 38,300 visits a month. Thanks to e-mail, PWSA (USA) has also been able to more effectively support families in the United States and provide support for those in many other nations who have no support system. As stated in a recent e-mail from Giorgio Fornasier, a parent from Italy who is the immediate past president of the International Prader-Willi Syndrome Organization (IPWSO), with which

PWSA (USA) is affiliated: “Technology is also a ‘means,’ not something to show we’re different, inferior, or superior. E-mail is a fantastic way to communicate and assist people, and the Internet a window in the world which any desperate family can open and realize the sun is shining.”

The Executive Director of PWSA (USA), Janalee Heinemann, states: “Our short-term goals are to support and educate parents and professionals and to save the lives of our children in crisis. Our long-term goal is to continue to enact our mission statement with a particular emphasis on *preventing* our children from getting into a crisis state. Our mission is not only to educate the families and professionals working with the syndrome, and to save the lives of our children, but also to foster the emotional well-being of our children and young adults with PWS. To give them a sense of worth in a society that shuns anyone different and views obesity as a psychological weakness is not an easy task. Today, understanding, acceptance, and wholeness are only in the dreams and wishes of our children and their families—but our ultimate goal.”

PWSA (USA) Educational Materials

Following is a selected list of educational products available through PWSA (USA) as of April 2005:

Publications in English

The Child With Prader-Willi Syndrome: Birth to Three, by Robert H. Wharton, M.D., Karen Levine, Ph.D., Maria Fragala, P.T., Deirdre C. Mulcahy, M.S., CCC–SLP. This booklet discusses the common concerns of the first 3 years and offers specific recommendations for early intervention strategies. A helpful and positive resource for families, physicians, early intervention worker, and other care providers. 34 pages (revised 2004).

Prader-Willi Syndrome: Handbook for Parents, by Shirley Neason, with subsequent revisions by members of the PWSA publications committee. A comprehensive booklet with pictures that covers birth to adulthood. Parent-to-parent handbook for understanding and managing issues related to PWS. 75 pages (revised 1999).

Nutrition Care for Children with PWS, Infants and Toddlers, by Janice Hovasi Cox, M.S., R.D., and Denise Doorlag, OTR. Provides answers to frequently asked questions about nutrition and feeding of infants and toddlers with Prader-Willi syndrome. 62 pages (revised 2004).

Nutrition Care for Children with PWS, Ages 3-9, by Karen H. Borgie, M.A., R.D. Covers calorie needs, supplements, diet planning and food management, and explains food exchange lists. 12 pages (2003).

Nutrition Care for Adolescents and Adults with PWS, by Karen H. Borgie, M.A., R.D. Covers essential diet information for families, caregivers, and residential service providers. 24 pages (2003).

Low-fat, Low-sugar Recipes for the Prader-Willi Syndrome Diet, by Donna Unterberger. Cookbook for the PWS diet filled with recipes designed

for use by the whole family. Great substitution list, fun snack recipes, mealtime tips, and full nutritional values calculated for each recipe. 156 pages (2003).

Physical Therapy Intervention for Individuals with PWS, by Maria Fragala, P.T. This booklet provides general information about physical therapy intervention. Includes copies of articles by Janice Agarwal, a physical therapist and mother of a young child with PWS. 11 pages.

Exercise and Crafts & Activities—A Collection of Articles. Contributions by Jennifer C. Deau, M.S., exercise physiologist, and other articles on muscle tone, upper body strength, exercise, and crafts and activities for the individual with Prader-Willi syndrome from infancy to adulthood. 44 pages (1998).

Behavior Management—A Collection of Articles. This booklet includes articles on behavior management and specific concerns, such as use of psychotropic medications, management of skin picking, toilet training, social skills teaching, and more from PWSA's newsletter, *The Gathered View*, and other sources. 79 pages (revised 2003).

Educator's Resource Packet, including the booklet *Information for School Staff: Children with Prader-Willi Syndrome*, by Barbara Dorn, R.N., and Barbara J. Goff, Ph.D. This packet is a resource for educators that includes a teacher's handbook for the student with PWS, an accompanying worksheet about PWS-related issues and interventions for school staff, as well as related articles from PWSA's *The Gathered View*. (2003).

Health and Medical Issues for the Individual with Prader-Willi Syndrome—A Collection of Articles. From the pages of PWSA's newsletter, *The Gathered View*, and other sources, this booklet brings together articles on many aspects of PWS written primarily for the layperson. Covers management of obesity, various medical conditions associated with the syndrome, vision and dental issues, sexual development and sexuality, genetics of PWS, and more. 121 pages (revised 2004).

Prader-Willi Syndrome Medical Alerts. Important resource for parents to give to their child's doctor, emergency room staff, caregiver, etc. Briefly presents cautions regarding aspects of PWS that could lead or contribute to life-threatening situations. A useful pocket-sized handbook written by PWSA's medical professionals. 20 pages (2005).

Growth Hormone and Prader-Willi Syndrome—A reference for families and care providers, by Linda Keder in consultation with both medical and parent advisors. Covers growth patterns in PWS, research on the effects of growth hormone treatment, and details on using GH therapy in children with PWS. 52 pages (2001).

Prader Willi Syndrome Is What I Have, Not Who I Am! A book of "feelings" written by children and young adults with PWS, collected by Janalee Heinemann, Executive Director of PWSA (USA). This book gives insights into the lives and thoughts of people dealing with PWS on a daily basis. A portion of the book opens the door to journal writing and an opportunity for the reader with PWS to share their feelings. (2005).

Michael and Marie, Children with Prader-Willi Syndrome, by Valerie Rush Sexton and Debbie Erbe Fortin, illustrated by Bonnie Branson.

Written by two teachers, this storybook is designed to be read to elementary school age children to educate classmates of special needs children about the need to understand and help create a friendly and safe environment for all children. (2003).

Sometimes I'm Mad, Sometimes I'm Glad—A Sibling Booklet, written by Janalee Heinemann, M.S.W., in the voice of a sibling of someone with PWS. Recognizes the range of feelings that arise in having a brother or sister with the syndrome, based on the author's observations in raising her son with PWS and his siblings. (1982).

Supportive Living Care Plan for an Adult with PWS in Placement. This comprehensive book/CD will help families create a plan that is specifically designed to help staff and supportive personnel provide predictable, consistent, and accountable care and advocacy for the adult with PWS. This is available in both a notebook format and in a changeable CD that can be adapted to explicitly meet the needs of each individual. (2002).

Video Products

"PWS—The Early Years" (42 minutes). This video offers help and practical suggestions for those families with a young child newly diagnosed with PWS. Genetics, medical, early intervention, and family issues are presented, personalized with family interviews. Although focusing on young children, this video is a wonderful resource for schools and families with children of all ages. PAL European version available. (2002).

"Prader-Willi Syndrome-An Overview for Health Professionals" (35 minutes). This outstanding medical overview video is a must for all health care professionals who are not "experts" on Prader-Willi syndrome. It deals with all the major genetics and health care issues of the child with PWS. PAL European version available. (2002). New DVD version available (revised 2004).

"Understanding Prader-Willi Syndrome" (18 minutes). A professionally produced video with good practical advice for individuals who work with persons who have PWS, designed to train service provider staff on the needs of individuals with PWS.

Publications in Spanish/Literatura en Español

Mi Hija tiene el síndrome de Prader-Willi Y ahora qué? by Carlos Molinet Sepulveda. The experience from a Chilean father's perspective of searching for answers about his daughter, who was born in 1988 with Prader-Willi syndrome in a country with no knowledge or resources on PWS. He tells a moving story about the power of love and perseverance. (2003).

Guía Para Familias y Profesionales El Síndrome de Prader-Willi. Comprehensive book on the management of PWS, each chapter written by a specialist on the particular topic. Excellent reference tool. Reprinted thanks to Asociación Española Prader-Willi. Softcover, 400 pages. Also available in CD format.

Síndrome de Prader-Willi: Guía Para Los Padres, Familiares Y Profesionales, by Moris Angulo, M.D. An overview of the syndrome in booklet form for parents and professionals. 16 pages (revised 2003).

Note: This is not a comprehensive list of PWSA's publications and videos, and available titles may change over time. For a current order form that includes all available products contact the PWSA (USA) office or visit the Association's Web site: www.pwsausa.org.

Index

A

- Academic achievement, 13, 31, 32, 254. *See also*
 - Educational considerations
 - growth hormone therapy-related improvement in, 209, 233
 - obstructive sleep apnea-related impairment of, 122
 - relationship with genotype, 36, 37
- Acanthosis nigricans, 170
- Acromicria, 13, 16, 206
- Adams forward bending test, 115
- Adaptive behavior, 260
- Adenomas, hepatic, 138, 163
- Adenotonsillectomy, 128
- Adiponectin, 170
- Adipose tissue. *See also* Body fat; Fat mass
 - metabolism in, 20–21
- Adolescents, with PWS
 - behavioral and psychological disorders in, 17, 259, 314, 317, 320–321, 347–350, 480–481
 - educational and social issues affecting, 314–315, 344–355
 - excessive body fat in, 297
 - motor and developmental delays in, 296–299
 - natural medical history of, 14–17, 99
 - patello-femoral syndrome in, 297–298
 - physical appearance of, 297
 - transition to young adulthood, 356–369, 437–438
- Adrenal gland, hypofunction of, 100
- Adrenarche
 - muscle function during, 113
 - normal, 108, 169
 - premature, 53, 99, 108, 169, 175, 178, 221
- Adults, with PWS
 - behavioral disturbances in, 17–18
 - growth hormone therapy for, 220–221, 222–224, 227–228, 229
 - natural medical history of, 14–17, 99
 - posture in, 299
 - speech and language disorders in, 277, 278–280
- Advocacy issues
 - government-sponsored services, 446–447
 - national approach to, 440–447
 - parental for adult services, 365, 368
 - school discipline and expulsion, 443–444, 448–456
 - sexuality, 444, 457–464
- Aggression, 13, 110–111, 347–348, 415, 449–450
- Agility, growth hormone therapy-related increase in, 208
- Agouti-gene-related peptide (AGRP), 165, 167
- Alzheimer’s disease, 136–137
- Amblyopia, 134
- Ambulation, onset age of
 - normal, 285, 293
 - in PWS, 11, 13, 98, 285, 293, 294, 295–296, 479
- Amenorrhea, 15, 111
- Androgen replacement therapy, 110–111. *See also* Testosterone, replacement therapy
- Androgens, 104
- Anemia, 411, 412
- Anesthesia, disordered thermoregulation during, 131, 133
- Angelman syndrome, 4, 6, 34–35, 58, 59, 61, 74, 137, 457, 458, 475
 - genetic tests for, 84–85, 87–88
- Angiotensin-converting enzyme inhibitors, 407
- Anthropometry, 179–180
- Anticonvulsant agents, as behavioral disturbances treatment, 482
- Antihypertensive agents, vasodilating effect of, 409–410

- Anxiety, 320, 322, 324
- Apnea, 98, 99, 119. *See also*
Obstructive sleep apnea
- Appetite disorder, in PWS,
19–20, 165–166. *See also*
Food-related behavior;
Hyperphagia
- Appetite-regulatory peptides,
165, 166–168
- Appetite-suppressing
medications, 39, 174–175,
323–324, 331, 338–340,
482
- Apraxia, of speech, 274
- Arousal abnormalities, 120, 285,
306
- Asperger syndrome, 262, 263
- Astigmatism, 134
- Atherosclerotic heart disease,
130
- Attentional deficits, 256, 320
- Augmentative/alternative
communication (AAC)
intervention, 274, 277
- Autism and autism spectrum
disorders, 34, 262–264
- Autonomic dysfunction,
132–133, 160
- Aversive therapy, 453–454
- B**
- Bariatric surgery, 175, 176–177
- Basal metabolic rate (BMR),
168
- Beckwith-Weidemann
syndrome, 7, 54
- Behavioral contracts, 330, 331,
348, 349, 351
- Behavioral disturbances, 7,
32–34, 257–264, 318–323,
347–350
in adolescents, 17, 259, 314,
317, 320–321, 347–350,
480–481
in adults, 17–18
age-related changes in, 11,
13, 53, 257–260, 313–314,
317, 362
developmental “epochs”
in, 319–321
in the classroom, 305,
345–346, 442–444
among preschool-age
children, 310–311
crisis interventions for,
442–444
legal aspects of, 443–444
management of, 305, 310,
443, 453, 454
effect of growth hormone
therapy on, 26, 209, 231,
482
effect on speech and
language, 273, 276
effect on transition to young
adulthood, 361–363
genotypes associated with,
35–36, 38, 321
as indication for genetic
testing, 51
measurement of,
inadequacies in, 247
in school-age children,
313–314
siblings’ reactions to, 435
in toddlers, 13
variability in, 321
in the workplace, 365, 374
- Behavioral management
for adolescents, 17, 348–350
behavioral change strategies
in, 327, 328–331
environmental interventions
in, 324–325, 327–328,
335–336, 385–387, 481
of food-related behaviors,
324–325
in inpatient care facilities,
414–415, 418–419
parental conflict about,
432–433
with pharmacotherapy,
39, 327, 331, 338–340,
482
in residential care facilities,
388–390
in schools, 305, 310, 443, 453,
454
social workers’ assistance in,
436
in the workplace, 375–378
- Behavioral phenotype, 319, 320,
339
- Bioelectrical impedance, 184,
188, 228
- Birth weight, 11
- Bisphosphonate therapy, 112,
118, 300
- Bisulfite restriction analysis
(BRA), 78, 85, 246
- Biting behavior, 32, 33
- Bladder cancer, 138
- Blood glucose testing, 221–222.
See also Glucose
tolerance testing
- Blood studies, in PWS, 28–29
- Bloom syndrome, 6, 230
- Body composition, 173. *See also*
Body fat; Fat mass; Lean
body mass; Muscle mass
effect of growth hormone
therapy cessation on, 227
effect on drug therapy
response, 339
growth hormone/insulin-like
growth factor-1
deficiency-related, 202
growth hormone therapy-
related improvement of,
224
measurement of, 22–23,
179–188
- Body fat. *See also* Fat mass
bioelectrical impedance
assessment of, 184, 188,
228
excessive. *See also* Obesity
detrimental effects of,
168–171
relationship with lean
body mass, 173
visceral, 170, 180
imaging of, 186
- Body mass index (BMI)
definition of, 163
during growth hormone
therapy, 227
in obesity/morbid obesity,
23, 163, 396, 398
in overweight, 164
- Body orientation, 286
- Body shape, 297
- Bone age, 26, 169
radiographic assessment of,
222, 223, 226
- Bone mass, peak, 116–117
- Bone maturation, PWS-related
acceleration of, 201
- Bone mineral density (BMD), in
PWS, 24–25, 116–117
in adolescents, 99
in adults, 223–224

- assessment of, 24–25, 117–118, 185, 187, 188
 effect of growth hormone therapy on, 206, 207, 227
 in obesity, 169
 in osteoporosis, 116–117
- Brain imaging studies, 22, 29–30
- Brain tumors, effect of growth hormone therapy on, 230
- Breast cancer, 138
- Breast development, 15, 108
- Bruininks-Oseretsky Test of Motor Proficiency, 298–299
- C**
- Calcium deficiency, as osteoporosis cause, 116–117, 118
- Calcium supplementation, 24, 118, 420
- Calorie requirements, 18, 325, 396
 overestimation of, 396
 for weight control. *See* Calorie restriction
- Calorie restriction
 effect on lean body mass, 173
 during growth hormone therapy, 233
 as obesity hypoventilation treatment, 403, 405
 for weight loss, 23, 172, 173
 for weight maintenance, 23–24, 172, 173
- Cancer, 137–138. *See also specific types of cancer*
 growth hormone therapy-related, 230, 231
 as mortality cause, 100, 137–138
- Carbamazepine (Tegretol), renotoxicity of, 410
- Carbohydrates, 172, 173–174
- Carbon dioxide narcosis, 399
- Carbon dioxide retention, 399, 403, 404
- Cardiomegaly, obesity hypoventilation syndrome-related, 399, 401, 406
- Cardiovascular disease, 130, 220
 as mortality cause, 99, 100, 122
- Case management, for adult services, 354, 366
- Catch-up growth, failure of, 225
- Celexa (citalopram), 109
- Cellulitis, 18, 409
- Central nervous system, involvement in PWS, 246–247
- Cerebrovascular disease, 122
- Children's Institute, Pittsburgh, Pennsylvania, 395
- Cholecystokinin, 20, 166
- Cholesterol levels, 28
- Chromosome 15q11-q13 region, 5, 6–7, 58–68, 74–89
 cancer-associated
 chromosome 15 abnormalities in, 138
 chromosome 15 translocations and rearrangements in, 59, 61, 74–75
 deletions in, 3–7, 59, 60, 61
 in Angelman syndrome, 59, 61
 behavioral and cognitive deficits associated with, 35–36
 DNA methylation patterns of, 75
 frequency and recurrence risk of, 63
 genetic testing for, 8–10, 55, 86, 87
 phenotype associated with, 34–38
 relationship to academic underachievement, 254
 relationship to behavioral disturbances, 259
 relationship to speech and language defects, 279–280
 relationship to visual perception, 37–38
 types I and II, 38, 61, 65–66, 254, 259
- DNA replication pattern analysis of, 10
- genes downstream from, 65
 genes located in, 63–65
 imprinting defects in, 3, 7, 58–59, 62, 63–65
 mouse models of, 65–68
- Citalopram (Celexa), 109
- Clitoris, 103, 104–105
- Clomiphene citrate, 109, 110
- Clotrimazole, 410
- Cluttering, 275
- Coenzyme Q10, 28–29, 136–137, 209
- Coercion, 328–329
- Cognitive deficits, 30, 31–32, 246–247, 321–323, 481
 effect on adaptation to change, 397
 effect on speech and language, 273–274
 measurement of, inadequacies in, 247
 obstructive sleep apnea associated with, 122
 processing deficits, 254–256
- Cognitive functioning, 30–31, 250–253
 assessment of, 251–252
 effect of growth hormone therapy on, 233
 stability of, 253
- Collecting behavior, 250, 386
- Community living skills, 31–32, 260
- Community services, 437
- Comprehensive care guidelines, for PWS, 231–233, 473–484
- Compulsive behavior, 33–34, 36, 259, 260, 262. *See also* Obsessive-compulsive behavior
- Computer skills training, 313
- Conservatorship rights, 358. *See also* Guardianship
- Constipation, 161, 162
- Contingent reinforcement, 418–419
- Contraception, 112, 457–458, 460–461
- Coronary artery disease, 18, 130
- Cor pulmonale, 19, 122, 127, 128–130, 396, 399, 403–408

- Cranial nerves, 154, 155
 Craniopharyngioma, 39, 203, 204
 Craniosynostosis, 180, 225–226
 Creatinine levels, 407
 Creutzfeldt-Jakob disease, 205
 Crisis interventions
 inpatient, 395–425
 for behavioral and psychological crises, 397, 410–412, 414–422
 for medical crises, 397–412
 therapeutic milieu in, 416–421
 for legal issues, 443–445
 national approach to, 440–447
 Cryptorchidism, 12, 14, 53, 98, 107–108
 bilateral, 104, 106
 evaluation of, 105–106
 pathophysiology of, 102–105
 treatment of, 107–108
- D**
 Daily living skills, 260
 Dating behavior, 351, 458–459
 Dehydroepiandrosterone, 28
 Deletion. *See* Chromosome 15q11-q13 region, deletions in
 Delivery, of neonates with PWS, 11
 Delusions, 265
 Dentition and dental health
 PWS-related disorders of, 25, 155, 156, 161
 caries, 13, 156, 157
 effect on speech and language, 273
 enamel hypoplasia, 13, 25
 infections, 138, 156, 157
 malocclusion, 25
 prevention of, 157
 role in mastication, 154
 Depression, 317
 in adolescents, 348, 481
 in adults, 220
 effect of growth hormone therapy on, 209, 220
 onset age of, 11
 psychiatric hospitalization for, 415
- Dermatofibrosarcoma, 138
 Developmental delays, 11, 13, 307, 308, 313
 as indication for genetic testing, 51
 onset age of, 52–53
 physical therapy interventions for, 284–301
 in adults, 299–300
 in infants, 285–293
 in preschool children and adolescents, 296–299
 in toddlers, 293–296
 Developmental milestones
 in infants with PWS, 11, 12, 285
 Diabetes mellitus
 Type 1, 102, 169
 Type 2
 complications of, 19, 178
 diagnostic criteria for, 170–171
 effect of growth hormone therapy on, 40, 221–222, 230
 inpatient treatment for, 409
 management of, 19, 178, 325, 409
 obesity-related, 18, 19, 169–170
 obstructive sleep apnea-related, 122
 prevalence of, 100, 161
 screening for, prior to growth hormone therapy initiation, 221–222, 224
 symptoms of, 170
 vascular disease associated with, 130
 Diagnosis. *See* Prader-Willi syndrome (PWS), diagnosis of
 Diarrhea, 161, 162
 Dietitians, in residential care facilities, 385, 391
 Diets
 calorie-controlled. *See* Calorie restriction
 for diabetes mellitus management, 178, 409
 high-protein, low-carbohydrate, 173–174
 for obesity management, 23–24, 324. *See also* Calorie restriction
 Digestion, 157–158
 Disomy (UPD), maternal uniparental, 5–6, 61–62, 74
 clinical features associated with
 behavioral and cognitive deficits, 31, 35, 259
 ophthalmologic disorders, 133
 phenotype, 74
 psychosis, 264–265
 speech and language deficits, 279–280
 verbal IQ scores, 254
 visual memory and perception, 37–38, 255
 frequency and recurrence risk of, 63
 genetic testing for, 10, 86, 246
 heterodisomy 15, 6
 isodisomy 15, 6
 mouse models of, 66–67
 Diuretics, as edema treatment, 405, 407
 Divalproex sodium, 482
 DNA methylation, in genomic imprinting, 58
 DNA methylation pattern, in PWS, 75
 DNA methylation testing, 9, 10, 55, 100
 polymerase chain reaction (PCR), 5, 10, 76, 78, 82–85
 bisulfite restriction analysis (BRA), 78, 85, 246
 fluorescence melting curve analysis, 78, 84
 with methylation-sensitive restriction enzyme, 78, 84–85
 methylation-specific, 78, 83–84
 reverse transcriptase, 76, 78, 85
 prenatal, 87, 89
 relationship with diagnostic criteria, 54

- Southern blot analysis, 5, 55, 76, 77, 78, 79–80, 87–88
- Dolichocephaly, 7, 12, 16
- Down, J. Langdon, 3
- Down syndrome, 169, 258, 357
- Drug therapy. *See* Pharmacotherapy
- Dual-energy x-ray absorptiometry (DXA), 22–23, 25, 117, 181, 185, 187, 188
- during growth hormone therapy, 222, 223–224, 226, 227
- T- and Z-scores in, 117–118
- Dysgeusia, 156
- Dyslipidemia. *See also* Lipid profiles
- obesity-related, 18
- E**
- Edema
- of the legs, 18, 398, 399, 408–409
- obesity hypoventilation syndrome-related, 400, 401, 403, 404, 405, 406
- peripheral, 229, 231
- pulmonary, 129, 130, 399, 407
- Educational considerations, 13–14, 302–316
- for adolescents, 314–315, 344–355
- behavioral disturbances, 347–350
- transition planning and services, 344–351, 352–354, 356–369
- behavioral disturbances, 305, 310–311, 345–346, 442–444
- crisis interventions, 442–444
- for infants and toddlers, 307–308
- legislative basis for, 302–304
- mainstreaming, 13–14, 443
- medical issues, 306–307
- one-on-one aides, 442
- for preschool children, 308–311
- program models for, 304–306
- for school-age children, 311–314
- school discipline and expulsion, 448–456
- alternate placements and, 453–454
- functional behavioral assessments (FBAs) and, 452
- parents' right of due process and, 452–453, 456
- social workers' role in, 437–438
- termination of formal education, 17
- Embolism, pulmonary, 100
- Emesis (vomiting), 19, 160
- Emotional lability, 259
- Emotions, 322–323
- Employment, 370–371
- pitfalls and successes in, 373–380
- sheltered, 359, 364
- transition to, 359
- vocational training for, 17, 354, 363–365, 370–380
- work placement options for, 371–373
- continuum of, 372–373
- sheltered workshops, 371–372, 374, 375–376
- supported employment, 372
- work enclaves, 372, 374
- Energy expenditure, 20, 22, 168.
- See also* Resting energy expenditure (REE)
- growth hormone therapy-related increase in, 478
- Environmental interventions, in behavioral management, 324–325, 327–328, 335–336, 346, 385–386, 481
- Epilepsy, 137
- Epiphyses, closure of, 226, 228
- premature, 99
- Esotropia, 133–134, 135
- Estrogen replacement therapy, 111–112
- Estrogens, 108, 110
- Executive functions, 256
- Exercise
- in adults, 300
- aerobic, 296, 300
- benefits of, 483
- for diabetes mellitus management, 178, 409
- food-related motivation for, 326
- in growth hormone-treated children, 233
- guidelines for, 39
- in inpatient care facilities, 418
- obesity hypoventilation syndrome-related intolerance to, 401
- for obesity management, 324
- in school-age children, 299, 311–312
- Exercise physiologists, 392
- Exotropia, 134, 135
- Extended family, 435–436
- F**
- Facial anomalies, 7, 8, 12, 50, 53, 54, 228
- Factitious disorder, 413
- Failure-to-thrive, 11, 12, 22, 25, 98, 156, 483
- Family support and advocacy, 426–439
- Family therapy, 481
- Fat embolism, 168
- Fatigue, 336
- Fat mass. *See also* Body fat; Obesity
- normal, 164
- in PWS, 21
- growth hormone deficiency-related increase in, 220
- growth hormone therapy-related changes in, 206, 207, 209, 219, 225
- measurement of, 22–23
- pathogenesis of, 164–168
- relationship to lean body mass, 164, 179
- relationship to physical activity, 113
- subcutaneous pattern of, 22–23
- visceral, 23
- Feeding difficulties, 7
- mouse models of, 66–67

- Feeding difficulties (*cont.*):
 in neonates and infants,
 12–13, 22, 52, 285–286,
 290, 318, 483
 in toddlers, 294
- Feet
 length measurement of, 180,
 493
 small, 13, 16, 297
- Fenfluramine, 323
- Fertility/infertility, 15, 110, 457
- Fertility testing, 110
- Fetus, PWS in, 51–52, 98, 285
- Fever, 412
- Fluid retention. *See also* Edema
 obesity hypoventilation
 syndrome-related, 400,
 401
- Fluorescence *in situ*
 hybridization (FISH),
 8–9, 10, 54, 76, 81, 86,
 87–88, 458
- Fluorescence melting curve
 analysis, 78, 84
- Fluoxetine (Prozac), 15, 109,
 338, 482
- Follicle-stimulating hormone
 (FSH), 105, 108–110
- Food
 acidic, 156, 157
 decreased interest in, 412
 regurgitated, 160–161
 as reinforcer, 325–327
- Food-related behaviors,
 248–250, 318–319, 397.
See also Hyperphagia
 age-related development of,
 11–14, 258, 318–319
 crisis intervention for,
 441–442
 effect on transition to young
 adulthood, 361–362
 management of, 18, 24, 173,
 174, 307, 323–327,
 324–325, 335–336, 345,
 346, 347, 348–350, 414,
 415, 433–434, 445–446
 in inpatient and residential
 care facilities, 385–386,
 387, 417–418
 onset age of, 53, 483
 prevalence of, 249, 320
 as school suspension cause,
 443
- types of, 248, 249–250, 318,
 397
 in the workplace, 371,
 373–375, 376
- Food security, psychological,
 324, 417–418
- Fractures, 18–19, 24, 117, 118,
 169, 284
- Fragile X syndrome, 431–432
- Friendships, development of,
 311, 314, 351
- Frustration intolerance, 319,
 320, 333–335
- Fungal infections, as result of
 intertrigo, 410
- G**
- Gait abnormalities, 293, 294,
 295
- Gamma aminobutyric acid
 (GABA), 19, 22, 28, 34,
 37, 65, 121, 136, 137
- Gastric dilatation. *See* Stomach,
 dilatation of
- Gastroesophageal reflux,
 159–160
- Gastrointestinal system
 disorders of, 153–200
 physiology of, 153–163
- Gastrostomy feedings, in
 infants, 171–172
- Gender ambiguity, 417
- Genetic counseling, 87
- Genetic subtypes, of PWS, 58.
See also Chromosome
 15q11-q13 region;
 Disomy, maternal
 uniparental; Genomic
 imprinting defects
- Genetic tests, 3–4, 5–6, 7,
 8–9, 10, 74–93, 246, 319,
 476
 for Angelman syndrome,
 84–85, 87–88
 chromosomal analysis, 55
 DNA methylation testing, 9,
 10, 55, 100
 fluorescence *in situ*
 hybridization (FISH),
 8–9, 10, 54, 76, 81, 86,
 87–88, 458
 for imprinting defects, 86,
 87–88
 indications for, 51, 52, 54
- microsatellite analysis, 75–76,
 86
- parental reactions to,
 428–429
- polymerase chain reaction
 (PCR), 5, 10, 76, 78,
 82–85
 bisulfite restriction analysis
 (BRA), 78, 85
 fluorescence melting curve
 analysis, 78, 84
 with methylation-sensitive
 restriction enzyme, 78,
 84–85
 methylation-specific, 78,
 83–84
 reverse transcriptase, 76,
 78, 85
 prenatal, 87, 89
 reference laboratories for,
 87–89
 relationship with diagnostic
 criteria, 54, 55–56
 reverse transcriptase
 polymerase chain
 reaction (PCR), 76, 78,
 85
- Southern blot analysis, 5, 55,
 76, 77, 78, 79–80, 87–88
 for uniparental disomy, 86,
 87–88
- Genitalia
 abnormalities of. *See also*
 Cryptorchidism;
 Hypogonadism;
 Micropenis
 evaluation of, 105–106
 in females, 103, 105
 in males, 12, 14, 53, 98,
 102–104, 105–108
 pathophysiology of,
 102–105
 treatment of, 106–108
 development of
 in females, 104–105
 in males, 103–104
- Genomic imprinting
 defects of, 3, 7, 34, 58–59,
 62–65, 76
 tests for, 86, 87–88
 definition of, 6
- Genotype-phenotype
 relationships, in PWS,
 34–38

- Genotypes, of PWS. *See* Genetic subtypes, of PWS
- Genu recurvatum, 297
- Genu valgus, 13
- Germ cell tumors, 107
- Gesell and Armtruda
Developmental and
Neurological
Examination, 287
- “Getting stuck” behavior, 258–259, 320
- Ghrelin, 20, 29, 167
- Glucose levels, 28
- Glucose tolerance, 20
testing of, 40, 170–171, 221–222, 224, 226, 228
- Gonadal failure, primary, 109, 110
- Gonadal stimulation testing, 106
- Gonadarche, 108
- Gonadotropin, 104, 106, 107, 109
deficiency of, 14, 104, 105, 109, 110
- Gonadotropin-releasing hormone, 108, 109
deficiency of, 110
- Group homes, 319, 360, 361, 362–363
scarcity of, 365, 367
- Group therapy, 419
- Growth charts, of individuals
with PWS, 487–503
- Growth hormone, 201–241
deficiency of, 7, 26, 28, 201–204
growth hormone
replacement for. *See* Growth hormone therapy
mechanisms of, 223
as osteoporosis cause, 116
pathophysiology of, 201–204
relationship with obesity, 26
respiratory effects of, 121–122
as short stature cause, 202
receptor defects, 203
secretion of, 202–203
stimulation tests, 202–203, 222–223
- Growth hormone/insulin-like growth factor-I axis
assessment of, 222
deficiency of, 40, 202–204, 220
- Growth hormone-releasing factor deficiency, 223
- Growth hormone therapy, 13, 22, 26–28, 40, 97, 204–233, 474–480
in adults, 40, 220–224
with cadaver-derived growth hormone, 204–205
complications of, 228–231
diabetes mellitus, 26
pseudotumor cerebri, 40
scoliosis exacerbation, 26, 40
thyroid hormone deficiency, 229–230
comprehensive care and, 231–233
contraindications to, 122, 230
dosage, 112, 224–225, 227
effects of
behavioral and
psychosocial, 26, 209, 231, 482
body composition and metabolism, 26, 27, 206–207
on caloric requirements, 172, 325
on eating behavior, 174
on muscles, 207–208
on physical appearance, 53, 232, 233, 482–483
on physical parameters, 475–480
respiratory, 121, 128, 207–209
on skeletal growth, 206
on voice characteristics, 275
- Food and Drug Administration approval for, 299
history of, 204–205
for hypotonia, 113
in infants, 209, 219–220
laboratory testing during, 226, 228
non-PWS applications of, 205, 220, 229
- scoliosis monitoring during, 114
surveillance databases on, 205, 206, 208, 230
with synthetic growth hormone, 205–206, 224–225
testing prior to, 221–224
transition to adult therapy regimen in, 226–227, 228
- Growth rate, in PWS, 25, 201–202
- Growth regulation, role of imprinted genes in, 7
- Growth retardation, 13
prenatal, 11
- Growth spurt, 16
absence of, 25
- Growth standards, for PWS, 15–16
- Guardianship, 18, 358, 438
- H**
- Hallucinations, 264, 415
- Haloperidol, 338, 482
- Hand-eye awareness, 286
- Hands, length measurement of, 180, 492
small, 13, 16, 297
- Head banging, 32
- Head circumference
measurement, 180, 219, 225–226, 491
- Health insurance coverage, 366
- Heartburn, 159, 160
- Heart failure
obesity-related, 18
right-sided. *See* Cor pulmonale
- Height, genetic factors in, 26
- Height growth, measurement of, 179
- Height velocity, 16
effect of growth hormone therapy on, 225, 226, 477
- Hematocrit levels, 399
- Hemoglobin levels, 399
- Hepatoblastomas, 138, 163
- Hernia, 103, 107–108
- Heterodisomy 15, maternal, 6
- Hip dysplasia, 118–119
- Hoarding behavior, 35, 259, 261, 386, 481

- Hormone replacement therapy
 in females, 111–112
 in males, 14, 106, 110–111,
 112, 113
 for osteoporosis prevention,
 118
- Hospitalization, crisis
 interventions during. *See*
 Crisis interventions,
 inpatient
- Hunger, 165. *See also* Appetite
 disorder; Hyperphagia
- Huntington's disease, 136–137
- Hydrocele, 107–108
- Hydrocephalus, 226
- Hyperglycemia, 409
- Hyperphagia, 7, 245, 320. *See*
also Food-related
 behaviors
 behavioral disturbances
 associated with, 257
 characteristics of, 248–249
 effect on insulin-like growth
 factor-1 levels, 203, 204
 etiology of, 165, 250, 323
 lack of control of, 307
 management of, 323–324
 among preschool-age
 children, 311
 in the classroom, 311
 onset age of, 11, 12–13, 53
- Hypersomnia, 414
- Hypertension, 18, 128–130, 229,
 231, 409–410
- Hyperthermia, 12, 131, 133–134
 malignant, 133, 134
- Hypocretins (orexins), 166–167
- Hypoglycemia, 221, 409
- Hypogonadism, 3, 7, 11, 14, 98,
 99, 108–112. *See also*
 Cryptorchidism;
 Micropenis
 as diagnostic criteria, 50
 evaluation of, 110
 hypogonadotropic, 14, 108,
 109, 110, 475
 hypothalamic, 417
 in males *vs.* females, 53
 treatment of, 110–112
- Hyponatremia, drug-related,
 420
- Hypopigmentation
 Angelman syndrome-related,
 65
 PWS-related, 4–5, 8, 12, 13,
 34–35, 65, 134–135, 374
- Hypopituitarism, 104, 221,
 229
- Hypospadias, 102–103
- Hypothalamic-pituitary-
 gonadal axis
 dysfunction, 28
- Hypothalamus
 injury to, 53–54
 PWS-related dysfunction of,
 14, 22, 29, 30, 39, 165,
 246, 247, 250
 role in autonomic nervous
 system, 132
 role in respiratory disorders,
 120–121
- Hypothermia, 11, 12, 131–132,
 133–134, 413–414
 during anesthesia, 131
- Hypothyroidism, 13, 162, 229
- Hypotonia, 112–113
 effect on participation in
 school-related activities,
 307
 effect on speech and
 language development,
 273, 274
 etiology of, 112
 fetal, 98, 104, 112
 histopathological studies of,
 112–113
 as indication for genetic
 testing, 51, 55
 in infants, 7, 276–277
 growth hormone therapy
 for, 207
 in mice, 68
 in neonates, 11–12, 52, 98,
 105, 112–113, 285, 318
 differential diagnosis of, 52
 as indication for genetic
 testing, 55
 relationship to
 gastroesophageal reflux,
 159
 of the ocular muscles, 135
 oropharyngeal, in neonates,
 155, 156
 as physical inactivity risk
 factor, 22
 of the respiratory muscles,
 121, 138
 in toddlers, 98–99
 treatment of, 113
- Hypoventilation, 17, 18–19, 99,
 119, 120, 121, 396. *See*
also Obesity
 hypoventilation
 syndrome
- Hypoxemia, 129, 130, 401
- Hypoxia, 398, 400, 402, 403,
 404, 407
- ## I
- IGF-I. *See* Insulin-like growth
 factor-I (IGF-I)
- Imprinting. *See* Genomic
 imprinting
- Impulsivity, 347–348
- Individual Family Service Plan
 (IFSP), 302–303
- Individual Habilitation Plan
 (IHP), 325
- Individualized Education Plan
 (IEP), 303, 304, 309, 310,
 311, 325, 357–358, 437,
 442–443
- Individuals with Disabilities
 Education Act (IDEA)
 and amendments,
 302–304, 437, 442, 449,
 451
 Manifestation Determination
 Review requirement of,
 451–452
 transition planning mandate
 of, 357, 358
- Infants, with PWS
 behavioral and personality
 characteristics of,
 257–258, 319
 clinical features in, 11–12, 52,
 98
 developmental delays in,
 307–308
 excessive fat mass in, 22
 feeding difficulties in, 12–13,
 22, 52, 98, 156, 276,
 285–286, 290, 483
 growth hormone therapy in,
 225–226
 “honeymoon” period in, 52
 motor skills deficits in,
 287–293
 nutritional management in,
 171–172
 speech delay in, 277

- underweight in, 12, 164
- Infections, 138–139
 cutaneous, 32, 138–139, 411
 dental, 138, 156, 157
- Infertility/fertility, 15, 109–110, 457
- Insulin, 28
 as growth hormone
 provocative agent, 222
 resistance, 19, 108, 169, 170, 178, 230, 231, 479
 therapy, 178, 409
- Insulin-3 (descendin), 103, 104
- Insulin-like growth factor-I (IGF-I), 227, 228, 476, 480
 deficiency of, 26, 113, 121, 202, 476, 480
- Insulin-like growth factor binding protein-3 (IGFBP-3), 202
- Intelligence quotient (IQ)
 scores, 13, 30–32, 247, 250–254, 255, 309, 321–322, 481
 relationship with behavioral disturbances, 348
 relationship with genotype, 13, 36, 37
- Intelligence tests, 251–252, 309
 inadequacy of, 247
- International Prader-Willi Syndrome Organization (IPWSO), 514–528
- Intertrigo, 410
- Intestines
 functions and physiology of, 153, 158
 PWS-related pathology of, 161–162
- Iris transillumination defects, 134
- Irritability, 259
- Ischemic heart disease, 130
- Isodisomy 15, maternal, 6
- K**
- Keyboarding, 313
- Kyphosis, 16, 114, 115
- L**
- Labhart, Alexis, 467–472
- Labia
 development of, 104–105
 hypoplasia of, 103, 105
- Laboratory tests. *See* Genetic tests
- Language. *See* Speech and language
- Larynx, PWS-related disorders of, 273, 274
- Lean body mass, in PWS
 effect of caloric restriction on, 173
 effect of dietary protein on, 173–174
 effect of growth hormone therapy on, 206, 207–208, 209, 219, 477–479
 proportionate relationship with fat mass, 164, 168, 179
- Learning disabilities, 246–247, 254, 309, 397, 481
- Learning strengths, of children with PWS, 312
- Learning weaknesses, of children with PWS, 312–313
- Legal issues
 guardianship, 18, 358, 438
 in the public arena, 444–445
 school-related, 443–444
 wills, 438
- Leptin, 20, 165, 167–168
- Leukemia, 137, 138
- Level systems, in behavioral reinforcement, 389
- Leydig cells, 14, 110
- Life expectancy
 in Down syndrome, 357
 in PWS, 18, 99–100, 319, 357, 381
- Life-sequence photographs, of PWS patients, 210–219, 232
- Lifestyle changes, 484
- Linear growth. *See also* Height growth; Height velocity
 age-related deceleration in, 16
 growth hormone therapy-related increase in, 476–477
 negative correlation with weight gain, 99
- Lipid metabolism, 479
- Lipid profiles, 20, 21, 28, 228
- Liver enzyme assays, 222, 228
- Liver tumors, 163
- Living arrangements, for individuals with PWS, 438. *See also* Residential care
- Lordosis, 114, 115
- Luteinizing hormone, 104, 105, 108–109, 110
- Lying, 13, 320
- Lymphoma, 138
- M**
- Malingering, 412–413
- Manipulative behavior, 13, 404, 405
- Marital relationship, of parents of children with PWS, 431–432
- Marriage, of individuals with PWS, 458, 459, 461
- Mastication, 154
- Mathematical ability, 14, 31, 254
- Medicaid, 446
- Medicaid Waiver programs, 371–372
- Medical care, in residential care facilities, 390–392
- Medical considerations, in PWS, 97–152. *See also* Gastrointestinal system; Growth hormone cardiovascular and cerebrovascular disorders, 128–130
 crisis intervention for, 396, 397–414, 440–442
 disorders of sexual development and maturation, 102–112
 musculoskeletal disorders, 112–119
 respiratory disorders, 119–128
 special considerations
 hypersomnia and daytime sleepiness, 414
 thermoregulatory disorders, 413–414
 unreliable self-reports, 412–413
- Medication seeking, 413
- Memory
 growth hormone therapy-related improvement in, 209, 233

- Memory (*cont.*):
 long-term, 14, 31, 255, 312
 short-term, 247, 254–255, 481
 auditory, 312–313
 visual, 31, 255
 visual-spatial, 37–38
- Menarche/menstruation, 15,
 99, 109, 228
 induction of, 15, 109–110
- Mental retardation, 3, 7, 309,
 481
 as indication for genetic
 testing, 51
 self-injurious behavior
 associated with, 33
 severity of, 30, 250–251,
 252–253, 321–322
- Metabolic rate, 168
 growth hormone therapy-
 related improvement of,
 206
 studies of, 20–22
- Metabolic syndrome, 169
- Metacognitive deficits, 256,
 481
- Metformin, 174–175, 178
- Microdontia, 155
- Micrognathia, 155, 273, 274
- Micropenis, 12, 53, 102, 104,
 106–107
- Microsatellite analysis, 61,
 75–76, 86
- Mineral supplementation, 175
- Mitochondrial DNA disorders,
 136–137
- MKRN3 gene, 6, 63–64
- Molecular genetics, of PWS. *See*
 Genetic subtypes, of
 PWS
- Molecular genetic tests. *See*
 Genetic tests
- Monosomy 15, 6
- Mood disorders, 264–265, 348,
 415
- Mortality causes, in PWS, 18,
 99, 100, 122, 128, 130,
 137–138, 361
- Motor skills
 delays in. *See* Developmental
 delays
 genetic factors in, 14
 of school-age children, 313
- Mouse models, of PWS, 66–68
- Muscle function, in growth
 hormone therapy,
 207–208, 209, 219, 226
- Muscle mass, in PWS, 17, 20
 growth hormone therapy-
 related increase in,
 207–208, 478–479
 as hypotonia cause, 112
 physical therapy-related
 increase in, 113
 in toddlers, 98–99
- Muscle tone, low. *See*
 Hypotonia
- Musculoskeletal disorders,
 112–119. *See also*
 Hypotonia; Kyphosis;
 Osteoporosis; Patello-
 femoral syndrome;
 Scoliosis
- Myocardial infarction, as
 mortality cause, 100
- Myopia, 13, 134
- N**
- Naloxone, 323
- Narcolepsy, 120, 414
- Narrative skills, deficits in, 273,
 275–276, 279
- Nasogastric tube feedings, in
 neonates and infants,
 156, 157, 171–172, 483
- National Cooperative Growth
 Study (NCGS), 205
- National Dissemination Center
 for Children with
 Disabilities (NICHCY),
 304, 442
- NECDIN (NDN) gene, 6, 63, 64,
 67
 in mouse (*Ndn*), 64, 67, 68,
 110, 121, 135
- Neonates, with PWS
 clinical features in, 11–12, 52,
 285–286
 feeding difficulties in, 12–13,
 22, 52, 285–286, 318
 growth hormone therapy in,
 221
 motor skills deficits in,
 285–287
 nasogastric tube feedings in,
 156, 157, 171–172, 483
 natural medical history of,
 98
- obesity in, 98
 sucking reflex in, 12, 155,
 171–172, 285, 318, 483
 underweight in, 153
- Neurobehavioral symptoms, of
 PWS, 257–265, 481. *See*
also Behavioral
 disturbances
- Neurodevelopmental aspects,
 of PWS, 245–271
- Neuroleptic malignant
 syndrome, 133, 134
- Neuroleptics, 338, 414, 420
- Neuropsychological testing,
 419
- NIPA1 gene, 38, 65
- No Child Left Behind Act of
 2001, 302, 303–304
- Nonalcoholic fatty liver disease
 (NAFLD), 163
- Noncontingent reinforcement,
 418
- Non-steroidal anti-
 inflammatory drugs, 407
- Nurses, in residential care
 facilities, 391
- Nurturing behavior, 351, 354
- Nutritional management, of
 PWS, 16, 171–175, 324–
 325. *See also* Diets
 effective strategies for,
 433–434
 parental conflict about,
 432–433
 in residential care facilities,
 385–386, 391
- Nystagmus, 13
- Nystatin, 410
- O**
- Obesity, 3, 7, 8, 18–24, 98,
 163–178
 causes of, 19
 complications of, 18–19,
 168–171, 396–397,
 398–410
 cellulitis, 409
 growth hormone
 deficiency, 202, 203–204
 hypertension, 409–410
 hypoventilation, 398–408
 insulin resistance, 178
 intertrigo, 410
 leg edema, 408–409

- obstructive sleep apnea, 121
 premature adrenarche, 175, 178
 crisis intervention for, 441–442
 definition of, 98, 163
 differentiated from
 overweight, 163, 164
 life-course photographs of, 210–219
 measurement of, 22–23
 metabolic studies of, 20–22
 morbid
 definition of, 398
 inpatient interventions for, 396
 non-PWS-related, 24, 54
 onset age of, 18, 22, 53
 physical therapy
 interventions for, 299
 relationship to intelligence scores, 30
 weight management in, 23–24, 39, 174–175, 176–177, 482
- Obesity hypoventilation syndrome, 398–408
 clinical presentation of, 400–403
 as excessive daytime sleepiness cause, 414
 management of, 403–408
 as mortality cause, 18
 pathophysiology of, 399–400, 405–406
- Obsessions, 17, 313, 317, 362, 363, 481
- Obsessive-compulsive disorder, 13, 17, 33–34, 36, 260–264, 347. *See also* Hoarding behavior; Skin picking
- Obstructive sleep apnea, 12, 120, 121–122, 125–127, 168–169
 evaluation of, 122–128
 growth hormone therapy's effect on, 221
 onset age of, 11
 treatment of, 128
- Occupational therapy
 in educational setting, 305, 310
- for oropharyngeal hypotonia, 156
 with toddlers, 296, 308
- Olanzapine, 482
- Ophthalmologic disorders, 133–135
- Opioids (endorphins), 167
- Oppositional behavior, 319, 419
- Oral contraceptives, as hypogonadism treatment, 111–112
- Oral motor impairment, 285–286
 effect on speech and language development, 272, 273–274, 308
- Oral pathology, 155–156. *See also* Dentition and dental health, PWS-related disorders of
 effect on speech and language, 273, 274
 onset age of, 11
- Orchiopexy, 106, 107, 108
- Ordering behavior, 35, 261
- Oromotor therapy, 156, 157
- Oropharynx
 functions and physiology of, 153, 154–155
 PWS-related pathology of, 155–157
- Orthopedic disorders. *See also* Fractures; Kyphosis; Lordosis; Patellofemoral syndrome; Scoliosis
 obesity-related, 18
- Orthophoria, 134
- Orthopnea, 408
- Orthotics, for feet and ankles, 295
- Osteomyelitis, 139
- Osteoporosis, 116–119, 475
 in adults, 99, 220
 as fracture cause, 24, 117, 118, 284
 growth hormone deficiency-related, 220
 implication for physical therapy, 300
 scoliosis-exacerbating effects of, 114
 treatment and prevention of, 111, 112, 118, 220
- vitamin D deficiency-related, 175
- Ovarian failure, primary, 110
- Overweight
 body mass index in, 164
 childhood, definition of, 164
 differentiated from obesity, 163, 164
- Oxcarbazepine (Trileptal), renotoxicity of, 410
- Oxygen saturation, in obesity hypoventilation syndrome, 398, 399, 401, 402, 405, 406–407
- Oxygen therapy, 129, 403, 405–407
- Oxytocin, 22, 29
- P**
- Pain sensitivity, PWS-related
 decrease in, 11, 12, 14, 118, 135–136, 229, 412
- Panhypopituitarism, 221
- Parents, of children with PWS
 parenting styles of, 432
 social work interventions with, 426–439
 transitions-related
 experiences of, 363–368
- Parkinson's disease, 136–137
- Patello-femoral syndrome, 297–298
- Penis
 hypoplastic (micropenis), 12, 53, 102, 104, 106–107
 length measurement of, 106–107
- Peptides, appetite-regulatory, 165, 166–168
- Perseveration, 17, 311
- Personality traits, 11, 17, 257–258, 259, 260, 319
- Pfizer, 205
- P* gene, 12, 34–35, 61
- Pharmacotherapy. *See also* names of specific drugs
 appetite-suppressing medications, 39, 174–175, 323–324, 331, 338–340, 482
 for behavioral management, 39, 327, 331, 338–340, 482

- Phenotype-genotype relationships, in PWS, 34–38
- Phenotype variability, in PWS, 245
- Phentermine, 323
- Physical activity. *See also* Exercise
as obesity hypoventilation treatment, 403, 405
- Physical appearance. *See also* Facial anomalies
effect of growth hormone therapy on, 232, 233, 482–483
- Physical education programs, adaptive, 299, 347
- Physical inactivity
effect on energy expenditure requirements, 22
in school-age children, 298–299
- Physical performance, growth hormone therapy-related improvement in, 479
- Physical therapy, 99, 313
in growth hormone-treated children, 233
for hypotonia, 113
for motor and developmental dysfunctions, 284–301
in adults, 299–300
in educational setting, 305, 310
in infants, 285–293
in preschool children and adolescents, 296–299
in toddlers, 293–296
for respiratory disorders, 127–128
- Pica, 19
- “Pickwickian syndrome,” 400
- Pivoting, in behavioral management, 329, 331
- Play, repetitive, 311
- Plethysmography, air-displacement, 182, 187, 188
- Pneumonia, 122, 139, 441
- Point systems, in behavioral reinforcement, 389–390
- Polymerase chain reaction (PCR), 5, 10, 76, 78, 82–85
- bisulfite restriction analysis (BRA), 78, 85
- fluorescence melting curve analysis, 78, 84
with methylation-sensitive restriction enzyme, 78, 84–85
methylation-specific, 78, 83–84
reverse transcriptase, 76, 78, 85
- Polypharmacy, 413
- Polysarcia, 3
- Polysomnography, 126, 227
- Positioning, during sleep, 407–408
- Positioning devices, for infants with PWS, 288
- Posture, 13, 168–169, 286–287, 299
- Prader, Andrea, 467–472
- Prader-Willi psychiatric syndrome, 264
- Prader-Willi syndrome (PWS)
clinical features of, 7, 8, 9, 474
clinical stages of, 11–18, 22, 51–53
comprehensive care guidelines for, 231–233
comprehensive team treatment approach in, 475, 476, 483–486
definition of, 3
diagnosis of, 7–10
average age at, 7, 428–429
parental reactions to, 428–431
diagnostic criteria for, 7–8, 49–57, 246
first published report of, 467–472
frequency of, 9
genotype subtypes of. *See* Genetic subtypes, of PWS
“honeymoon” period of, 52
incidence and prevalence of, 3, 272, 475
multidisciplinary approach to, 39, 483–486
natural medical history of, 98–99
recurrence of, 3
symptoms, onset age of, 9
- Prader-Willi Syndrome Association (USA), 381, 421, 449, 529–534
- caloric requirements guidelines, 172, 175
- cancer survey study, 137–138
- Clinical Advisory Board recommendations on sleep-disordered breathing, 122, 123–125, 127
- Crisis Intervention Program, 440–447
- information sources, 364
- parent mentoring program, 430
- Prader-Willi syndrome organizations, 309
- Prader-Willi syndrome patients, life-sequence photographs of, 210–219, 232
- Pregnancy. *See also* Fetus
in women with PWS, 15, 109, 351, 457, 458
- Prenatal diagnosis, of PWS, 87, 89
- Primitive reflexes, 285. *See also* Sucking reflex
- Privacy, in inpatient care, 417
- Problem-solving ability, 414
- Progesterin, as hypogonadism treatment, 111–112
- Prolactin, 28
- Prosody, 272
- Protein, dietary, 173–174
- Prozac (fluoxetine), 109
- Pseudotumor cerebri, 40, 229, 231
- Psychiatric disorders, 264–265, 397. *See also* Psychosis
in adolescents, 481
as crises, inpatient treatment for, 415–416
relationship with body weight, 362
stress-induced, 397
- Psychological therapies, inpatient, 419
- Psychomotor development developmental delays in, 11

- growth hormone therapy-related improvement in, 209, 219, 479
- Psychosis, 17, 36, 317, 348, 481.
See also Psychiatric disorders
- Psychotropic medications, 331, 338–340, 415, 419–421.
See also names of specific medications
- as behavioral disturbances treatment, 17, 482
- as food-foraging behavior treatment, 174
- inpatient administration of, 419–420
- as neuroleptic malignant syndrome cause, 133
- as photosensitivity cause, 374
- renotoxicity of, 410
- Puberty. *See also* Adolescents; Adrenarche; Gonadarche; Menarche/menstruation delayed or absent, 14 growth spurt of, 16, 25, 99
- Pulmonary function testing, 126, 227
- Pulse oximetry, 401, 402
- Puzzle-solving ability, 14, 30–31, 36, 255, 256
- PW71B probe methylation test, 79, 80–81, 87–88
- PWS. *See* Prader-Willi syndrome (PWS)
- Q**
- Quality of life
assessment of, in growth hormone-treated patients, 224, 226
strategies for improvement of, 483–484
- R**
- Rashes, 18
- Reading skills, 14, 31, 312
- Rectal picking and digging, 32, 162, 397, 411–412, 415
- Red, Yellow, Green Diet, 418
- 5 α -Reductase, 103, 104
- Rehearsal strategies, 313
- Reinforced practice, 329–330, 331
- Reinforcers, in behavioral management, 330
food as, 325–327
non-food, 325
- Renal dysfunction, 204, 225, 410
- Repetitive behavior, 259, 260, 261, 262
- Residential care for adults, 381–394
advantages of, 306
behavioral management in, 388–390
environmental factors in, 385–387
food-related behavior management in, 385–386, 445–446
least restrictive environment in, 445–446
medical and ancillary care services in, 390–392
options for, 392–393
parental experiences with, 365, 367–368
planning for, 352
provider agencies' philosophies about, 382–385
sexuality issues in, 459–461
skill development programs in, 390
staffing and staff training for, 383, 384, 387–388
supervisory approaches in, 387–388
transition to, 359–361
- Respiratory disorders, 18–19, 119–128
etiology of, 208
evaluation of, 122–128
growth hormone therapy and, 122, 208, 221, 230
infections, 99, 100, 138
insufficiency/failure, 99, 100, 398, 400, 403
prevalence of, 161
respiratory compromise, 122, 420
scoliosis-related, 114–115
sleep-disordered breathing, 120, 122–128, 396
treatment of, 127–129
- Respiratory quotient (RQ),
growth hormone therapy-related decrease in, 207
- Response cost systems, in behavioral management, 389, 419
- Resting energy expenditure (REE), 20, 21, 207, 208, 233
- Reverse integration, in special education, 305–306
- Rigidity, behavioral, 17, 258–259, 319, 320
- Risperidone, 338–339
- Ritualistic behavior, 259, 260, 261, 262, 320, 321, 373
- Role-playing, 350–351
- Routines, need for, 39, 258, 310, 320, 321
- Rules of conduct, in inpatient care facilities, 417
- Rumination, 11, 160–161
- Russell-Silver syndrome, 7
- S**
- Saliva and salivation, 11, 25, 50, 138, 154, 155–156, 157
- Salt retention, 229, 231
- Sarcoma, pseudo-Kaposi, 139
- Satiety, 165
control of, 165
duration of, 249
- Schedules
difficulty in following, 322
in inpatient program, 417, 418
school, 346
- School buses, 345, 347
- School discipline and expulsion, 443, 448–456
alternate placements and, 453–455
functional behavioral assessments (FBAs), 452
parents' right of due process and, 452–453, 456
- Scoliosis, 16, 99, 113–116, 297
in adults, 99
bone mineral density in, 117
diagnosis of, 115
fat mass-related exacerbation of, 169

- Scoliosis (*cont.*):
 growth hormone therapy
 and, 114, 226, 227,
 228–229, 477
in utero, 98
 neuromuscular, 298
 non-PWS-related, 114–116
 onset age of, 11
 prevalence of, 100
 radiographic assessment of,
 222, 223, 298
 relationship to height
 growth, 179
 treatment of, 115–116, 128,
 298
- Scooter boards, 294
- Scratching, 337
- Scrotum, hypoplasia of, 102
- Seizures, 137
- Selective serotonin reuptake
 inhibitors (SSRIs)
 action mechanisms of, 109
 as behavioral disturbances
 treatment, 13, 482
 as food-related behavior
 treatment, 338
 menses-inducing activity of,
 109–110
 as obsessive-compulsive
 disorder treatment, 33
 side effects of, 133, 134, 339,
 420
 as skin picking treatment,
 339
 as temper tantrum treatment,
 39
- Self-advocacy, 365
- Self-endangerment, 397
- Self-esteem, development of,
 311
- Self-injurious behavior, 11,
 32–33, 35–36, 397,
 411
 psychiatric hospitalization
 for, 415
 rectal, 32, 162, 397, 411–412,
 415
- Seminomas, 107, 138
- Sensory function, in PWS,
 135–136
- Sensory integration
 dysfunction, 296
- Sequential processing deficits,
 255–256, 322, 481
- Serotonin, hormone-regulating
 activity of, 109–110
- Serotonin syndrome, 133, 134
- Sertoli cells, 14, 110
- Sertoli cell tumors, 107
- 7B2 gene abnormalities, 29–30
- Sex education, 112, 233, 351,
 457–458, 459, 463
- Sexual abuse, 461–463
- Sexual behavior, effect of
 growth hormone
 therapy on, 233
- Sexual development and
 maturation
 disorders of, 14–15, 99,
 102–112, 417
 normal
 in females, 104–105
 in males, 103–104
- Sexuality issues, in PWS, 351,
 457–464
 contraception, 111–112,
 457–458, 460–461
 dating behavior, 351, 458–459
 legal issues related to, 443,
 444
- Sexually transmitted diseases,
 112, 459
- Short stature, 3, 15–16, 25–26,
 297
 as diagnostic criteria, 50
 environmental
 accommodations for,
 386
 as final adult height, 201
 growth hormone therapy for.
See Growth hormone
 therapy
 idiopathic, 204
 insulin-like growth factor-I
 levels in, 203
 obesity-associated, 201–202
 premature adrenarche and,
 175, 178
 relationship to midparental
 height, 201
 “Shutdowns,” 347
- Siblings, of children with PWS,
 435
- Sibutramine (Meridia), 323
- “Simultaneous processing,” as
 a learning strength, 312
- Skinfold thickness
 measurement, 22–23, 180
- Skin infections, 32, 138–139, 411
- Skin picking, 32, 135, 245, 259,
 321, 410–411
 in adolescents, 314
 age-related development of,
 259
 as diagnostic criterion, 50
 genotype associated with, 35
 management of, 39, 331, 337,
 339, 411
 prevalence of, 9, 32, 161, 320
 rectal, 162
 in school-age children, 311
 as skin infection cause, 32,
 138, 411
 testosterone patches and, 111
- Sleep, positioning during,
 407–408
- Sleep-disordered breathing,
 120, 396. *See also*
 Obstructive sleep apnea
 evaluation of, 122–128
- Sleep disorders, 17, 119, 120
 evaluation of, 122
 excessive daytime sleepiness,
 11, 17, 122, 259, 414
 prevalence of, 100, 161
- Slipped capital femoral
 epiphysis (SCFE), 40,
 229, 231
- Small-for-gestational age, 204,
 225
- Snoring, 19, 126
- snoRNA* gene, 6, 68
- SNRPN* gene, 6, 10, 29, 59, 61,
 67, 68
- SNRPN* probe methylation test,
 76, 79–80, 81–82, 83–85,
 86, 87–88
- SNURF* gene, 6, 59, 61, 67, 68
- Social skills, 337
 deficits in, 263, 322–323
 age-related increase in,
 258–259
 facilitation, in the classroom,
 305
 growth hormone therapy-
 related improvement in,
 209
 training, 39, 310, 315, 350–351
- Social Security Administration
 (SSA) benefits, for
 individuals with PWS,
 366, 446, 504–513

- Social services interventions, 426–439
- Somatic complaints, 412–413
- Somatotropes, 202
- Somatotropin. *See* Growth hormone
- Southern blot hybridization analysis, 5, 55, 76, 77, 78, 79–80, 87–88
- Special Olympics, 299, 300, 311, 437
- Speech and language disorders of, 31, 247, 256, 272–283, 285, 290, 292, 321, 481
- characteristics of, 272–276
- clinical research study of, 277–280
- cognitive function effects of, 322–323
- developmental course of, 276–277
- fluency disorders, 275
- genetic factors in, 277–278, 279–280
- glossary of terms related to, 281–282
- interventions for, 308
- neonatal, 98
- poor speech development-related, 273–274
- in school-age children, 312–313
- treatment of, 274, 277, 280
- verbal language deficits, 275–276
- voice characteristics, 273, 274–275, 279
- written language deficits, 276
- normal development of, 285, 286, 289, 290
- Speech therapy, 156, 296, 308, 309, 310, 313
- Sports participation, 299, 311–312, 437
- Special Olympics, 299, 300, 311, 437
- Starvation syndrome, 250
- Steatosis, 163
- Stereoscopic vision impairment, 13
- Stomach dilatation of, 161
- functions and physiology of, 153, 157–158
- overeating-related rupture of, 396
- PWS-related pathology of, 159–162
- Stop-redirect-reinforce technique, 330, 331
- Strabismus, 4–5, 7, 11, 13, 98, 134, 135
- Strength, growth hormone therapy-related increase in, 207–208
- Stress responses, in PWS families, 429
- Stress vulnerability, 321, 322, 397, 414–415
- Strokes, as mortality cause, 100
- Stubbornness, 13, 245, 258, 317, 319, 320, 347–348, 442–443
- Stuttering, 275
- Sucking reflex, 12, 155, 171–172, 285, 318, 483
- Sudden death, 159, 230–231, 399
- Suggestibility, 413
- Suicidality, psychiatric hospitalization for, 415
- Swallowing, process of, 154–155
- Syndrome of inappropriate antidiuretic hormone (SIADH), 410
- T**
- Taste, 154, 156
- Teeth. *See* Dentition and dental health
- Telecanthus, 134
- Temper tantrums, 17, 33, 245, 259, 308–309
- in adolescents, 17, 314, 347–348
- age-related development of, 53, 258, 319
- in the classroom, 310
- effect on transitions in young adults, 362, 363
- in residential care facility residents, 387
- in school-age children, 311
- in toddlers, 13
- treatment of, 34
- vocational training and, 364
- in the workplace, 365
- Teratomas, ovarian, 138
- Testes descent of, 103–104
- development of, 103
- retractile and gliding, 102
- small, 102
- spontaneous ascent of, 107
- undescended. *See* Cryptorchidism
- Testicular carcinoma, 107
- Testicular torsion, 107
- Testosterone fetal deficiency of, 104
- as genital abnormalities indicator, 105, 106
- replacement therapy, 14, 106, 110–111, 112, 113
- role in male sexual development, 103, 104
- stimulation test, 106
- Theft, 13, 443, 444–445
- Therapeutic milieu, 414–421, 422
- Thermoregulatory disorders, 12, 130–134, 413–414
- Thinking abstract, 256, 322–323
- rigid, 332–333
- Thioridazine, 338, 482
- Thromboembolism, 409
- Thyroid function testing, 221
- Thyroid hormone monitoring, during growth hormone therapy, 229
- Thyroid-stimulating hormone (TSH) deficiency, 229
- Thyroxine deficiency, 229–230
- Time-out, 330, 331
- Toddler Infant Motor Evaluation (TIME), 219
- Toddlers behavioral and personality characteristics of, 257–258
- food-related behaviors in, 318–319
- motor and developmental delays in, 293–295, 307–311
- natural medical history of, 98–99

- Toddlers (*cont.*):
 personality traits in, 12–13, 257–258, 319
- Topiramate, 174, 339, 405
- Tourette's syndrome, 34
- Tracheostomy, 128, 407
- Transition
 to community living, 359–361, 365, 367–368
 difficulty with, 320
 to employment, 17
 to middle or high school, 344–351
 to work, 359
 to young adulthood, 356–369
 parental experiences with, 363–368
 timetable for, 353, 354
- Triglycerides, 21
- Trisomy 15, 6, 35, 62, 87
- Trisomy 18, 11–12
- Turner syndrome, 169, 204, 225, 230
- U**
- Ulcers, 100
 cutaneous, 18
 rectal, 32, 162, 412
 treatment of, 410
- Undernutrition
 growth hormone therapy-related, 233
 in neonates, 98
- Underweight, in neonates and infants, 12, 164
- Uniparental disomy. *See*
 Disomy (UPD), maternal uniparental
- United States Department of Education, 303, 304
- United States Department of Vocational Rehabilitation, 372
- United States Social Security Administration, 446, 504–513
- Uvulo-palato-pharyngoplasty, 128
- V**
- Vasodilators, 129
- Ventilation, effect of positioning on, 407–408
- Ventilator dependence, 173
- Verbal skills, 14, 275–276
- Visual evoked potentials, 5
- Visual perception, 30, 31, 37, 255
- Vitamin B₁₂, absorption of, 158
- Vitamin D deficiency, 116, 118, 175
- Vitamin supplementation, 24, 118, 175
- Vocational training, 17, 314, 354, 370–380
 continuum of, 372–373
 parental experiences with, 363–365
- Vomiting (emesis), 160
- W**
- Waist circumference, 180
- Walking. *See* Ambulation
- Walking programs, 113, 300, 404, 418
- Water retention, 229, 231
- Weight gain
 negative correlation with linear growth, 99
 onset age of, 53
 during psychiatric hospitalization, 416
- Weight management, 23–24, 319, 482
 with bariatric surgery, 175, 176–177
 in hypertension, 409
 with pharmacotherapy, 39, 174–175, 323–324, 331, 338–340, 482
 in respiratory disorders, 128
- Werdnig-Hoffman syndrome, 11–12
- Wheelchair-dependence, 99, 168–169
- Willi, Heinrich, 467–472
- Williams syndrome, 263, 276, 431–432
- Wills, 438
- Wrightslaw, 304
- X**
- Xerostomia (“dry mouth”), 25, 156–157



A

B

Figure 1.3. Frontal and profile views of two males (patient **A** is 8.5 years of age, with the chromosome 15q11–q13 deletion [seen in Figure 1.1]; patient **B** is 11 years of age, with maternal disomy 15) with Prader-Willi syndrome. Note the typical facial appearance (e.g., narrow bifrontal diameter, almond-shaped eyes, triangular mouth), small hands and feet, characteristic obesity, and hypopigmentation (seen in patient **A** with the 15q11–q13 deletion). Modified from Butler, *American Journal of Medical Genetics* 1990;35:319–332.¹⁷



Figure 1.4. Representative fluorescence *in situ* hybridization (FISH) using a SNRPN probe from the chromosome 15q11–q13 region (red color), a centromeric probe from chromosome 15 (green color), and a distal control probe from chromosome 15q (red color) showing the absence of the SNRPN signal close to the centromere on the deleted chromosome 15 from a subject with Prader-Willi syndrome.

Color Plate II




Figure 1.5. Five-year-old boy with Prader-Willi syndrome before (top) and after 3 months of growth hormone (GH) treatment (bottom). Note the improved body habitus, muscle bulk, and reduced fat. The patient was able to increase total caloric intake, and he had increased activity and wakefulness. Reprinted with permission from S.B. Cassidy, "Prader-Willi syndrome in the new millennium: introduction," *The Endocrinologist* 2000;10(4) Suppl 1: 1S-2S. Copyright©2000 by Lippincott Williams & Wilkins.